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The Hsp90 chaperone complex associates with the telomerase enzyme, facilitating the 
assembly of the ribonucleoprotein complex. While previous data from our laboratory indicate 
that Hsp90 and p23 remain stably associated with (functionally active) telomerase, more recent 
experiments suggest that these chaperones associate with telomeres independent of telomerase, 
presumably through a specific interaction with telomere binding proteins. The current study 
examines the novel interactions between TRF2, TRF1, TIN2 and TPP1 and molecular 
chaperones (Hsp90, Hsp70, p23). In vitro and in cell experiments have shown an interaction 
xiv 
 
between TRF1 and TRF2 and the molecular chaperones Hsp90 and Hsp70. Inhibition of Hsp90 
using drugs that specifically block ATPase activity results in an increased association of TRF1 
and TRF2 with Hsp90 to presumably stabilize the telomere associated proteins to the telomere. A 
definitive explanation as to the mechanisms underlying the chaperone/telomere associated 
protein interaction has yet to be determined and further studies examining chaperones’ 
contribution to telomere structure and function are underway. A better understanding of the 
telomeric proteins and Hsp90 and their roles in nuclear events is important, as both have 
extremely important functions in the cell.  
Our current working hypothesis is that chaperone proteins associate with TRF2, TRF1, 
TIN2 and TPP1 to facilitate telomeric protein-protein interactions and protein-telomere binding 
in both cancer and normal cells. The interaction between chaperones and telomere binding 
proteins may eventually provide a better understanding of telomeric structure and function. 
Defining the mechanisms of telomeric protein regulation is important in the development of new 
therapeutic approaches for targeting telomeres to induce dysfunction. Clinical trials are 
underway employing drugs targeting Hsp90 in cancer cells and given the results here, these 
Hsp90 compounds likely cause telomere alterations.  
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Chapter 1 
Review of Current Literature 
 
TELOMERE PROTECTION 
Telomere dysfunction and the t-loop 
Telomeres, the ends of linear eukaryotic chromosomes, play a major role in maintaining 
chromosomal stability and may provide a target for cancer treatment and/or prevention. Muller 
and McClintock (1938, 1941) first theorized that telomeres act to distinguish the ends of the 
chromosomes as natural ends, not damaged DNA, and protect the end of the chromosome. 
Telomeric DNA is a nucleoprotein complex made up of non-coding DNA which, in humans, 
ranges in size from 2kb-20kb (Cech, 2009) and consists of tandem repeats of short, double 
stranded, guanine rich sequences of TTAGGG, a single stranded 3’ overhang, and associated 
proteins. These components allow the telomere to form the t-loop to differentiate the ends from 
broken DNA, which is crucial in preventing the activation of double-strand break repair 
mechanisms. Two telomeric proteins, TRF1 and TRF2, bind directly to the telomeric DNA and 
complex with other proteins including TIN2, Tankyrase1/2, TPP1, Rap1, POT1 and the Mre11 
complex (Figure 1, top panel). Together they function to organize the linear chromosomal ends 
into the protected t-loop structures (Figure 1, bottom panel) (Griffith, et al., 1999). Investigators 
have shown these proteins also regulate length and help to prevent genetic instability that has 
been associated with short telomeres. 
The structure of the t-loop is formed by the end of the telomere folding back on itself. 
This circular segment is made up of duplex telomeric DNA bound by TRF1. The 3’overhang of 
single stranded telomeric DNA invades the duplex DNA so that the TTAGGG repeat strand is  
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Figure 1. The telomere structure and associated proteins. Top panel shows telomeric binding 
proteins and their known interactions with associated proteins. TRF1 and TRF2 bind the 
telomeric DNA, while many of the associated proteins interact with TRF1 and/or TRF2 without 
binding the DNA directly. Bottom panel displays the hypothesized t-loop structure, indicating 
that TRF2 aids in the invasion of the 3’ overhang into the duplex DNA while TRF1 coats the 
telomeric DNA. Adapted from de Lange, 2005.  
3 
 
displaced at the loop-tail junction. TRF2 appears to promote this loop formation by facilitating 
the invasion of the 3’ end, while TRF1 helps to coil the duplex DNA on itself (Figure 1, bottom 
panel). Tankyrase, a telomeric poly(ADP)ribose polymerase, inhibits the binding of TRF1 to the 
telomere and may therefore also function in the regulation of the t-loop (Smith, et al., 1999).  
Sequestering the telomeric ends into these t-loop structures prevents cellular exonuclease 
activities and telomerase from acting on the DNA (Griffith, et al., 1999). Shortened telomeres 
fail to form t-loops, contributing greatly to genomic instability. As evidenced through the use of 
a dominant negative TRF2 (DNTRF2) mutant, open t-loops induce the activation of DNA 
checkpoints, including signaling through ATM and p53 (Karlseder, et al., 1999).  
With each cell division telomeric DNA is progressively lost due to the end replication 
problem, in which normal lagging strand replication fails to completely copy chromosome ends, 
leaving a gap between the final RNA priming event and the terminus. As this shortening 
continues over many cell divisions, the telomeres reach a critical length where they elicit a 
cellular senescence response in normal human cells (Levy, et al., 1992) Critical shortening 
results in dysfunctional telomeres in cells that have bypassed the senescence checkpoint and 
cause chromosomal instability, resulting in end-to-end fusions, dicentrics, breakage of DNA, 
missegregation, and chromosomal rearrangements (Counter, 1996; McClintock, 1941). Telomere 
shortening often results in extremely high levels of genetic instability, which can eventually 
contribute to tumorigenesis. Cancer cells activate telomerase to aid in lengthening telomeres, 
resulting in cellular immortalization. Short telomeres have been found in many carcinomas, 
including invasive breast cancers (Odagiri, et al., 1999; Griffith, et al., 1999), basal cell 
carcinoma (Han, et al., 2009), hepatocarcinomas, lung carcinomas (Oh, et al., 2005; Matsutani, 
et al., 2001), prostate cancer (Meeker, et al., 2002), bladder cancer (Wu, et al., 2003), esophageal 
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cancer (Shammas, et al., 2004), and gastric cancer (Liu, et al., 2009), suggesting that telomerase 
can maintain short but functional telomeres in tumor cells. This evidence also suggests that 
telomeric proteins and stable t-loops play a major role in protection against cancers. 
 
Telomeric Proteins  
Described as the Shelterin protein complex, the telomere binding proteins TRF1, TRF2, 
POT1(Protection of Telomeres 1) and associated proteins TIN2, Rap1, and TPP1, are defined as 
proteins abundant at the telomere but not elsewhere, present throughout the cell cycle, and 
functioning only at the telomere, thereby having high specificity to the telomeric repeats (de 
Lange, 2005).  The six components of the Shelterin complex fractionate together, with TIN2 
tethering TPP1 to TRF1 and TRF2 thereby connecting TRF1 to TRF2 for stability. This, in turn, 
directly binds Rap1 (Liu, et al., 2004; Ye, et al., 2004). POT1 is the only Shelterin protein to 
bind the 3’ single strand overhang of the telomere and also associates with TRF1 (Kelleher, et 
al., 2005). Proteins associated with the telomere that do not fall into the criteria of Shelterin 
components include: Mre11/Rad50/Nbs1, ERCC1/XPF, the WRN helicase, the BLM helicases, 
DNA-PKcs, PARP2, Tankyrase 1 and 2, PINX1 and RAD51D, many of which are classified as 
DNA damage proteins (Table 1).  
Telomere repeat binding factors 1 and 2 (TRF1 and TRF2) are paralogs that bind directly 
to the double strand region of the telomere (Chong, et al., 1995; Bilaud, et al., 1996; Broccoli, et 
al., 1997; Bilaud, et al., 1997) and play a major role in regulating the length of the telomere (van 
Steensel and de Lange, 1997; Smorgorzewska, et al., 2000). Their domain architecture is similar 
in that they share a hinge region, known as the TRF homology (TRFH) domain, which contains 
amino acids for homodimerization or homomultimerization. This hinge region brings together  
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Table 1. Telomere-associated proteins (reviewed in Karleseder, et al., 2003).  
Protein  Function at Telomere kDa pI 
TRF1 Sequester chromosome ends in t-loop, coat telomere 60 6.5 
TRF2 Major protective factor, 3’ overhang invasion to t-loop 65/69  9.2/9.22 
TIN2 Capping, length control 40 9.21 
hPOT1 Regulates telomere elongation via telomerase, binds TRF1 72 6.82 
PTOP/PIP1 Binds TRF1 and TRF2, blocks telomerase access to telomere  58 4.38 
hRAP1 Interacts with TRF2, t-loop/elongation regulation 50 7.02 
MRE11 Regulation of t-loop, interacts with TRF2 81 5.82 
NBS1 Regulation of t-loop, interacts with TRF1 and TRF2 95 6.91 
RAD50 Regulation of t-loop, interacts with TRF2 180 6.89 
Tank 1/2 Inhibits TRF1 binding to telomere, regulation of t-
loop/telomerase 
100/ 
116 
7.05/ 
7.2 
Ku70/80 Regulates capping  70/80 6.7/5.8 
XRCC1 Resistance to DNA damaging agents 70 8.83 
PARP1 DNA base excision repair and single strand break repair  28 9.88 
DNAPKcs Regulates capping  460 7.8 
RAD51D Length maintenance and regulation 37 6.23 
RAD54 Telomere length maintenance 85 8.49 
Ku86 Regulates capping and length 86 12.37 
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the Myb helix turn helix DNA binding domain of both proteins, allowing for sequence specific 
binding on the telomere (Figure 2). Mutational studies in fission yeast of the telomeric protein 
Taz1 (an ortholog to TRF1 and TRF2) further implicates the importance of the TRFH domain in 
telomeric localization, DNA binding and dimerization (Fairall, et al., 2001), as well as 
association with other telomeric proteins. TRF1 and TRF2 do not heterodimerize and interact 
only through proteins contained in the Shelterin protein complex (Karlseder, 2003). In fact, the 
TRFH domain in both TRF1 and TRF2 has a specific recognition motif for different proteins, 
implicating the consensus sequence YYHKYRLSPL as a means for recruitment of telomere 
associated proteins. TRF2’s TRFH domain recognizes the motif [Y/F]XL, and the TRF2 
interacting proteins TIN2 and Apollo, as well as two previously identified proteins, PNUTS and 
MCPH1, bind this sequence (Kim, et al., 2009).    
As mentioned, TRF1 and TRF2 form complexes at the telomeric DNA through protein-
protein interactions with telomere associated proteins and other DNA damage proteins. TRF1 
binds TIN2 via a domain in the TRF1 homodimerization region (Kim, et al., 1999). TIN2 also 
exists in a complex with TRF1 and POT1 (Loayza and de Lange 2003). These interactions help 
to mediate telomere length control activity by TRF1 through modulation of the telomere 
structure. POT1 is a single stranded DNA binding protein that controls telomerase mediated 
telomere elongation (Loayza and de Lange, 2003). Another protein, TPP1, known by different 
names including PTOP, PIP1, and TINT1, recruits POT1 to the TRF1 complex and physically 
connects TIN2 and POT1 (reviewed by Colgin and Reddel, 2004). TRF1 is also regulated by the 
Tankyrases (1 and 2) (Smith, et al., 1998; Smith and de Lange, 2000) which inhibit TRF1’s 
protective function at the telomere. Tankyrase1 and 2 promote telomere elongation with long 
term overexpression and mediate the ADP-ribosylation of TRF1 to open the telomeric complex,  
7 
 
 
 
Basic TRFH/Dimerization
N
L
S
MybN C
Acidic TRFH/Dimerization
N
L
S
MybN C
TRF2 Rap1
TRF1 TIN2
TRF2
TRF1
 
 
Figure 2. The structure of TRF1 and TRF2. Both TRF1 and TRF2 possess a 
TRFH/dimerization domain, which contains recognition sequences for interacting proteins and 
homodimerization, a Myb DNA binding domain that binds the telomeric DNA and nuclear 
localization sequences. TRF1 differs from TRF2 at the N-terminal, with TRF1 having an acidic 
N-terminal and TRF2 having a basic N-terminal. Adapted from: de Lange, 2005. 
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which allows for access to the telomere by telomerase, resulting in elongation (Smith and de 
Lange, 2000).  
TRF2 interacts with many of the same proteins as TRF1, which thereby contribute to the 
association of TRF1 and TRF2. TIN2 binds TRF2 and mediates its end-capping function, 
interacts with both TRF1 and TRF2, and forms complexes with TRF1 and other interacting 
proteins (such as TPP1). Mutants of TIN2 result in a DNA damage response, indicating that the 
TIN2 complexes are important for both telomere capping and telomere length control (Kim, et 
al., 2004). TPP1 binds TRF2 as well as TRF1, acting as a secondary barrier against telomerase 
access to the telomere (reviewed by Colgin and Reddel, 2004). The Mre11 complex, consisting 
of a trimeric protein made up of Mre11/Rad50/Nbs1, normally helps maintain genomic integrity 
and processes double stranded breaks (DSBs) (Haber, 1998) and stably interacts with TRF2 
(Zhu, et al., 2000). Nbs1 interacts only with TRF2 at the telomeres in S phase, while the rest of 
the complex interacts throughout the cell cycle and also with TRF1 (Wu, et al., 2000). Possible 
roles for the complex and its interaction with TRF1 and TRF2 include providing sequence for the 
generation of 3’ overhangs at the telomere, contributing to the formation and maintenance of t-
loops, and/or contributing to the controlled resolution of the t-loops (de Lange and Petrini, 2000). 
Other proteins associated with the DNA damage response proposed to be associated with 
TRF1 and TRF2 include the DNA-PK (DNA-dependent protein kinase) complex, made up of 
Ku70, Ku80, and the catalytic subunit DNA-PKcs (Bailey, et al., 1999; d’Adda di Fagagna, et 
al., 2001; Goytisolo, et al., 2001; Hsu, et al., 2000; Samper, et al., 2000). DNA-PKcs plays a 
role in capping the telomere but not in regulation of length of the telomere (Gilley, et al., 2001). 
Ku80 regulates telomere length and capping; its absence showed a loss of telomeric sequence 
and increased telomere fusions (Espejel, et al., 2002; Jaco, et al., 2004; Samper, et al., 2000). 
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The PARP1 DNA repair protein, a poly(ADP-ribose) polymerase whose normal function is in 
DNA base excision repair and single strand break repair (D’Amours, et al., 1999), also has been 
found to act at the telomere (d’Adda di Fagagna, et al., 1999). RAD51 paralogs (RAD51B, 
RAD51C, RAD51D, and XRCC2 and XRCC3) are required in cells for normal levels of genetic 
recombination and resistance to DNA damaging agents. RAD51D is involved in maintaining and 
regulating telomere length, and inactivation of RAD51D results in cell death due to telomere 
uncapping (Tasounas, et al., 2004). RAD54, part of the homologous recombination (HR) 
machinery also plays a role in telomere length maintenance (Jaco, et al., 2003), although the 
exact mechanism is currently unknown.  
 
TRF2  
The telomeric multiprotein complex organizes the linear chromosome end into a protected t-
loop structure, which contributes to telomere length regulation and end protection (Griffith, et 
al., 1999). One protein in particular, TRF2, aids in protection of telomeres from end-end fusions 
by directing the invasion of the 3’ single strand overhang into duplex telomeric DNA, creating 
the t-loop (Griffith, et al., 1999; Stansel, et al., 2001). As noted previously, when normal somatic 
cells divide, telomeres continuously shorten until they reach a critical length, providing less 
substrate for telomere binding proteins, most notably TRF2, to maintain the t-loop structure and 
mask the telomere from DNA damage response machinery (Karlseder, et al., 2002). When 
telomeres are exposed due to critical shortening and the loss of the t-loop, they are recognized as 
damaged DNA. The resulting telomere dysfunction is associated with characteristic cytogenetic 
abnormalities: end-end fusions, anaphase bridges, radials, dicentric chromosomes, gene 
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amplification, and overall genomic instability, eventually leading to immortalization (Karlseder, 
et al., 2002). 
Overexpression of the dominant negative form of TRF2 (TRF2∆B∆M) (Figure 3) 
demonstrates how important TRF2 functions as a protective factor at the chromosome ends (van 
Steensel, et al., 1998). Removal of TRF2 from the telomere results in loss of the G strand 
overhang, which leads to ~15% of telomere ends fusing together, resulting in DNA bridges, 
fused chromosomes and overall genomic instability in the form of translocations, nondisjunction 
and aneuploidy (van Steensel, et al., 1998; Smogorzewska, et al., 2002). Absence of TRF2 also 
leads to both apoptosis and senescence, as well as a DNA damage response involving activation 
of p53 and expression of p21cip1/waf1, Bax and ATM kinase, so that the cell recognizes the lack of 
TRF2 as deprotected telomeres or damaged DNA (van Steensel, et al., 1998; Karlseder, et al., 
1999). The resulting dysfunctional telomeres are recognized and bound by 53BP1, γH2AX, 
RAD17, ATM, and MRE11. These DNA damage protein complexes are referred to as telomere 
dysfunction induced foci (TIFs). The induction of this DNA damage response is a hallmark of 
telomere dysfunction and characteristic of inhibition of TRF2 (Takai, et al., 2003).  
TRF2 levels are found to be at least two fold higher in breast tumor cell lines, indicating that 
elevated TRF2 levels are a frequent occurrence in breast cancer (Nijjar, et al., 2005). 
Overexpression of TRF2 increases the incidence of skin cancer in a transgenic mouse model and 
also induces premature aging through accelerated shortening of telomeres (Munoz, et al., 2005). 
Whether this is due to elevated telomerase activation or a decrease in the DNA damage response 
at short telomeres has yet to be resolved. There is evidence for TRF2 upregulation in a number of 
other cancers including basal cell carcinomas (Munoz, et al., 2005), breast tumors, 
hepatocarcinomas, and lung carcinomas (Oh, et al., 2005; Matsutani, et al., 2001). Additionally,  
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Figure 3. The structure of dominant-negative TRF2. TRF2∆B lacks the N-terminal basic 
domain, while the TRF2∆B∆M lacks both the N-terminal and the C-terminal Myb domain, thus 
preventing telomeric binding. The resulting absence of TRF2 at the telomere leads to telomere 
dysfunction and cellular senescence. Adapted from: van Steensel, et al., 1998. 
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TRF2 has been found at sites of DNA double strand breaks outside of the telomere (Bradshaw, et 
al., 2005), suggesting that TRF2 plays an important role, not just at the telomere, but at other 
sites of DNA damage. It may serve as an early indicator of genomic instability that could 
contribute to tumorigenesis. Elevated levels of TRF2 in various cancer cell lines also indicate a 
role as a marker for cancer and/or as a target for treatment. 
TRF2 has recently been identified as having a role in chromatin organization at the 
telomere (Figure 4). Telomeres contain nucleosomes that are more compact with shorter weaker 
spacing than other nucleosomes, similar to pericentric heterochromatin (Tommerup, et al., 1994; 
Fajkus, et al., 1995). TRF2 can generate positive supercoiling with an ability to condense DNA, 
requiring both the TRFH domain and the N-terminal DNA binding domain of TRF2. Electron 
scanning microscopy shows DNA as more condensed around TRF2 complexes, suggesting that 
TRF2 wraps the DNA around itself. In this nucleosome-type model, TRF2 induces the 
untwisting of nearby DNA, allowing for strand invasion through positive supercoiling, similar to 
what likely happens to form the t-loop (Amiard, et al., 2007). In a more recent study, transgenic 
mice with overexpressed TRF2 showed a decrease in histones H3 and H4, resulting in disrupted 
nucleosomal spacing specific to telomeric chromatin, suggesting that TRF2 may have an 
additional impact on nucleosomal organization at the telomere (Benetti, et al., 2008). Previous 
studies implicated telomere chromatin structure in the negative regulation of telomere length and 
protection against genomic instability, further indicating a distinct role for TRF2 in telomeric 
protection (Blasco, 2007; Baker, et al., 2009).    
The literature suggests a major role for TRF2 in the protection of the telomere. Although 
much has been studied as to the effects of loss of TRF2 (through the DNTRF2) and its protein-
protein interactions, the mechanisms surrounding how TRF2 protects the telomere have not been  
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Figure 4. TRF2’s role in chromatin remodeling. TRF2 binds the telomeric DNA, forming 
multimeric complexes that the telomeric DNA wraps around. This leads to positive supercoiling 
and looping of neighboring DNA, possibly inducing the invasion of single-stranded DNA into 
the duplex DNA, creating the t-loop structure. Adapted from: Amiard, et al., 2007. 
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examined as closely. As mentioned above, there is a suggested role in chromatin modeling and t-
loop formation. Further exploration is warranted. It is possible that dimerization of TRF2 
impacts its ability to bind the telomere or there may be other proteins involved in TRF2’s ability 
to stably associate with both the telomere and other Shelterin proteins. Elucidating these 
mechanisms may provide a better understanding of TRF2’s role in protection of the telomere.   
 
 
POST-TRANSLATIONAL MODIFICATION OF TELOMERIC PROTEINS 
Post-translational modification of telomeric proteins has not been widely researched. 
However, a number of protein kinases associate at the telomere to aid telomere maintenance. 
These include ATM and DNA-PKcs (d’Adda di Fagagna, et al., 2004). The following focuses on 
the telomere binding proteins TRF2 and TRF1 and their post-translational modifications, 
including phosphorylation, ubiquitination, and SUMOylation.  
 
Phosphorylation 
The addition of phosphate groups to a protein normally occurs on a serine, threonine or 
tyrosine and acts as a regulatory mechanism, often activating a protein that is in turn deactivated 
by dephosphorylation (as is the case with p53). Phosphorylation can also play a role in protein-
protein interactions and in protein degradation. Although few groups have studied the 
phosphorylation of TRF2, it has been determined that TRF2 is phosphorylated in vitro by the 
protein kinase Aurora C, a member of the Aurora protein family of serine/threonine kinases 
(Spengler, 2007). This phosphorylation has a role in telomere homeostasis in germ cells, where 
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Aurora C has previously been identified to function, and in chromatin remodeling at the 
telomere, as Aurora B has been implicated. However, further studies are required to show a 
definitive regulation (Spengler, 2007).  
As TRF2 is implicated in binding to sites of DNA damage (Bradshaw, et al., 2005), it is 
highly likely that TRF2 is phosphorylated in response to damage repair. Though a transient 
association, phosphorylated TRF2 was detected at sites of DNA damage after irradiation (IR), 
wherein the phosphorylated TRF2 comes off the telomere, associates with ATM and localizes to 
DSB sites elsewhere on the chromosome. This occurs rapidly, 30 minutes after IR and disappears 
by 8 hours. Cells that use the ALT pathway or undergo some sort of telomeric crisis also have 
phosphorylated TRF2 localized to the telomeres. The suggestion that TRF2 can localize to both 
telomeric damage sites and genome wide DNA damage implicates TRF2 in a global role of DNA 
damage protection (Tanaka, et al., 2005). Interestingly, the modification by ATM 
phosphorylation has also been shown to be associated with TRF1 (Kishi, et al., 2001). 
TRF1 is a target of phosphorylation for Polo-like kinase 1 (Plk1) through a priming event 
mediated by the Cdk1 protein kinase (Wu, et al., 2008). Phosphorylation by Plk1 seems to 
increase TRF1’s ability to bind to telomeric DNA in vitro as the Plk1 targeting site is within 
TRF1’s DNA binding domain. Chromatin immunoprecipitation (ChIP) experiments using either 
Plk1 depletion or mutation of the Plk1 targeting site strongly reduced TRF1’s ability to bind to 
the telomere (Wu, et al., 2008). Casein kinase 2 (CK2) mediates phosphorylation of TRF1 and 
affects telomeric binding in vitro as well as in vivo. Chemical inhibition of CK2 reduced TRF1’s 
ability to bind to the telomere and TRF1 was subsequently ubiquitinated and degraded, 
suggesting a role for phosphorylation in regulating normal TRF1 turnover (Kim, et al., 2008). 
The Akt/protein kinase B complex interacts directly with TRF1 and mediates telomere 
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shortening when overexpressed in an HTC immortalized liver carcinoma cell line, possibly by 
upregulating TRF1 levels. Akt’s role in genomic instability suggests that this function at the 
telomere may be a factor in its effects on tumorigenesis (Chen, et al., 2009). 
 
Ubiquitination 
Ubiquitination is a form of post-translational modification that involves the attachment of 
one or more ubiquitin monomer(s) to a protein, usually as a way to label proteins for degradation 
via the proteasome. Ubiquitination is an ATP-dependent reaction wherein Ubiquitin is activated 
by the E1 activating enzyme, producing an ubiquitin-adenylate intermediate. Ubiquitin is 
transferred to the cysteine of the E2 conjugating enzyme after which E3 ubiquitin ligases 
recognize the substrate and facilitate ubiquitin binding to its target protein (Figure 5) (reviewed 
in: Hershko and Ciechanover, 1998). 
As with phosphorylation of telomeric proteins, studies regarding ubiquitination of TRF1 
or TRF2 are rare. Because these two proteins play a large role in regulating telomere length 
homeostasis, it is likely that these protein levels must be maintained to ensure proper protection 
against telomerase, particularly regarding TRF1’s role in inhibiting telomerase access to the 
telomere. Two ubiquitin ligase proteins, RLIM and Fbx4, have been implicated in regulating 
TRF1 turnover by targeting it for proteasome-mediated degradation, thereby regulating the 
protein levels of TRF1 in the cell. Overexpression of both RLIM and Fbx4 reduced the half life 
of TRF1, with Fbx4 targeting TRF1 for ubiquitination by acting as an adaptor of the Cul1-based 
ubiquitin ligase complex (Lee, et al., 2006). The two ligases appear to act independently of one 
another and bind to different regions of TRF1 but may cooperate to degrade TRF1 when 
expressed at high levels (Her and Chung, 2009; Lee, et al., 2006). 
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Figure 5. The Ubiquitination Pathway. The pathway begins with the E1 activating-enzyme, 
which in an ATP dependent reaction activates and binds the glycine residue of ubiquitin and is 
then transferred to the cysteine of the E2 conjugating enzyme. In the final step, catalyzed by the 
E3 ligating enzyme, ubiquitin is linked to an ε-amino group on the substrate protein’s lysine 
residue. A polyubquitin chain is then formed, where the C-terminus of the ubiquitin subunit is 
linked to a lysine residue on the previous ubiquitin. Adapted from: Hershko and Ciechanover, 
1998. 
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TRF1 binds to Tankyrase1, which is a poly(ADP-ribose) polymerase (PARP) that is 
associated with the telomere. When TRF1 is ADP-ribosylated by Tankyrase1, it is unable to bind 
to the telomere, thus allowing telomerase access and inducing telomere elongation (Smith, et al., 
1998; Smith and de Lange, 2000). Tankyrase1 induces proteasome-mediated degradation of 
TRF1 both in vitro and in vivo, where the subsequent release of TRF1 from the telomeres after 
ADP-ribosylation signals ubiquitination and degradation of TRF1. However, PARP activity is 
not required for ubiquitination to occur, as this is an independent event that takes place after 
ADP-ribosylation in vitro (Chang, et al., 2003). It appears, in this case, that the unbound TRF1 is 
being targeted for degradation while being protected from degradation when bound to the 
telomere.  
Implications regarding bound TRF1 interacting with the E3 ligases mentioned above 
suggest that degradation of only unbound TRF1 is not always the case, and maintaining proper 
TRF1 levels also may be an important trigger for ubiquitination. A literature search revealed no 
studies regarding TRF2’s ubiquitination, but TRF2 levels at the telomere seem not to be as 
tightly regulated as TRF1.  
 
Sumoylation 
SUMOylation is a form of post-translation modification with a pathway similar to 
ubiquitin, though its roles in the cell are numerous compared to ubiquitin, including protein-
protein interaction, DNA binding, localization, and direction towards degradation. 
SUMOylation, the conjugation of SUMO to its target proteins, involves binding of the SUMO 
protein to a consensus sequence containing a ψKxE motif, where ψ is a hydrophobic amino acid 
and x is any amino acid. The pathway involves enzymes specific to SUMO, but it is similar to 
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the ubiquitin pathway. SUMO is synthesized by SUMO specific proteases (SENPs) and is 
conjugated to target proteins in an ATP dependent manner by the SUMO E1 activating enzyme 
(AOS1/UBA2) and the E2 conjugating enzyme (Ubc9) (Figure 6) (Wilson and Rangasamy, 
2001). E3 ligases also are involved, but seem only to play a role in specificity of target proteins 
and are not necessary for in vitro SUMOylation. SUMO and ubiquitin’s roles in the regulation of 
TRF2 may provide clues into TRF2’s actions at the telomere in normal and cancer cells. 
Promyelocytic leukemia (PML) bodies of ALT cells (which lengthen the telomere 
through homologous recombination not telomerase) are also known as ALT-associated PML 
bodies (APBs) and contain telomeric chromatin, Shelterin proteins, and DNA repair proteins. 
The results of several studies suggest the SMC5/6 (structural maintenance of chromosomes 5/6) 
holocomplex has a role in SUMOylation at the telomere, particularly TRF2 SUMOylation in 
ALT cells. The SMC5/6 complex contains a SUMO ligase called MMS1, which is also found in 
the APBs (reviewed in Reddel, 2007). MMS1 stimulates SUMOylation of TRF1, TRF2, TIN2 
and Rap1 whereas inhibition of TRF1 or TRF2 SUMOylation prevents APB formation 
altogether. Inhibition of MMS1 or SMC5/6 causes telomere shortening, an increase in end-end 
fusions and senescence in ALT cells, which inhibits the homologous recombination of the 
telomere (Potts and Yu, 2007). The SUMOylation of Shelterin suggests two roles in the cell: 1) 
recruiting Shelterin to the PML bodies so telomeres can recombine and lengthen or 2) 
SUMOylation of Shelterin already in the PML bodies to maintain the telomeres. The role of 
SUMOylation of Shelterin proteins has yet to be explored in cells not undergoing ALT telomeric 
recombination, and the effects demonstrated by Potts and Yu (2007) have not been identified in 
telomerase positive cells (Potts and Yu, 2007; Zhao and Blobel, 2005; Xhemalce, et al., 2007).  
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Figure 6. The SUMOylation Pathway. In an ATP-dependent step, SUMO is activated by 
binding to the E1-activating enzymes SAE1/2. SUMO is transferred to the E2-conjugating 
enzyme Ubc9. SUMO is then ligated to the substrate protein through an isopeptide bond formed 
between its C-terminal glycine and the ε-amino group of a lysine on the substrate protein (within 
the consensus sequence ψKXE where ψ is a large hydrophobic residue, X is any amino acid). 
SUMO is processed by proteases termed SUMO-proteases or sentrin-specific proteases (SENPs). 
Adapted from: Verger, et al., 2003. 
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Ku70 is another SUMOylated telomeric protein. Ku70 maintains telomeres by binding 
telomeric sequence and facilitating telomerase-mediated elongation in response to double strand 
breaks. Ku70 is transiently SUMOylated, which possibly results in increased protein levels 
through stabilization of the protein by SUMO. This is associated with overexpression of SUMO1 
or SUMO2 in the cell, not necessarily with increased SUMOylation of Ku70 itself (although a 
SUMOylated version of Ku70 is observed). SUMO may actually act on an ubiquitin ligase, 
preventing its ability to degrade Ku70 and thus stabilizing Ku70 levels, although this hypothesis 
has yet to be fully explored (Yurchenko, et al., 2007). 
 
CHAPERONES 
 Heat shock proteins (Hsps), or chaperone proteins, are ubiquitous proteins required for 
cell processes including folding of the nascent polypeptide chains, preventing protein 
aggregation, and transporting proteins across membranes (Hartl, 1996). They were first identified 
as prominent proteins expressed under higher temperatures, hence the heat shock name 
(Lindquist and Craig, 1988). Other cellular stresses also induce their expression, including 
exposure to heavy metals, oxidative stress and inflammation, leading to the alternative name 
stress proteins (Jolly and Morimoto, 2000). The heat shock proteins include Hsp100, Hsp90, 
Hsp70, Hsp60, Hsp40, and the small Hsps ranging from 20-25 kDa, most of which tend to be 
localized to the cytosol, ER, and mitochondria in normal cells. In tumor cells, chaperone 
expression is often elevated presumably to maintain homeostasis and to allow tumor cells to 
tolerate microenvironment alterations. This results in normally lethal mutations promoting 
oncogenesis (Whitesell, et al., 1994). One specific chaperone involved in this process is Hsp90, 
which has been shown to be overexpressed in breast cancer (along with Hsp70) and correlates 
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with poor prognosis (Grem, et al., 2005), making it an ideal target for therapeutic cancer 
treatment. 
 Chaperones have been identified in telomere biology through their association with 
telomerase. The Hsp90 chaperone complex (including Hsp70, Hsp40, HOP, and p23) is 
necessary for assembly of active telomerase and inhibition of Hsp90 blocks telomerase assembly 
(Figure 7) (Holt, et al., 1999). Additionally, continuous chronic inhibition of Hsp90 with the 
drug Radicicol results in telomere shortening of approximately 2.2kb over 2 months (Compton, 
et al., 2006). Because the telomere associated proteins are so important to maintaining genetic 
stability, an interaction with a stress protein such as Hsp90 may indicate that there either is a 
problem at chromosome ends or constant modulation of protein structure and function is 
necessary at the telomere.  
 
Hsp90 
Hsp90 is one of the most abundant proteins in a normal, unstressed cell, making up 1-2% 
of the total soluble cytosolic proteins (Lai, et al., 1984). In normal cells, Hsp90 is latent and 
uncomplexed. However, in tumor cells the Hsp90 chaperone is activated and complexed with co-
chaperones (Figure 8) (Kamal, et al., 2003). The Hsp90 family of chaperones has a variety of 
functions in the cell, including protein trafficking, refolding of proteins and degradation targeting 
of aggregated unstable proteins mediated by the proteasome (Nathan and Lindquist, 1995). 
Hsp90 activity is ATP dependent, and the N-terminal domain of Hsp90 contains a unique ATP-
binding site known as the Bergerat fold that promotes client and co-chaperone binding as well as 
the development of specific inhibitors (Prodromou, et al., 1997; Stebbins, et al., 1997). The 
central region, known as the hinge region, allows for protein binding and regulatory functioning  
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Figure 7. The Hsp90 Pathway. Hsp90 is associated with co-chaperones Hsp40, Hsp70, and 
HOP along with the client protein in its intermediate complex in its open conformation. In an 
ATP-dependent reaction, Hsp90 enters its active complex in a closed conformation, stably bound 
to the client protein, ADP and the co-chaperone p23. Finally, the mature client protein is released 
from the Hsp90/p23 complex. Adapted from: Kamal, et al., 2003. 
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Figure 8. Active Telomerase Assembly. Unassembled telomerase exists in two complexes: the 
hTERT catalytic component bound to the chaperones Hsp90, Hsp70, p23, HOP and Hsp40 and 
the hTR RNA component. In an ATP dependent reaction, Hsp70, HOP and Hsp40 come off the 
hTERT component, which then stably associates with the hTR component forming active, 
functional telomerase. Hsp90 and p23 remain bound to telomerase. Radicicol binds the ATP 
binding site of Hsp90, preventing it from properly binding the hTERT client protein. p23 is 
unable to remain associated to Hsp90 and hTERT is unable to bind correctly to hTR, resulting in 
non-functional telomerase assembly. Adapted from: Forsythe, et al., 2001. 
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(Bogatcheva, et al., 1999). The C-terminus primarily functions as the site for homodimerization 
(Minami, et al., 1994).  
Hsp90 exists in two isoforms: Hsp90α and Hsp90β. Hsp90α is the more inducible and 
stable form (Lees-Miller and Anderson, 1989). Homodimerization increases after heat shock (or 
stress) and results in hydrophobicity (Minami, et al., 1994). In stressed conditions, these dimers 
may associate into oligomers to promote Hsp90 binding to unfolded target proteins (Lanks, 
1989).  
As mentioned above, Hsp90, along with the co-chaperone p23, is required to assemble 
active telomerase through binding of the catalytic component, hTERT, and aids in assembly with 
the RNA component hTR (Holt, et al., 1999). Hsp90 and p23 remain stably associated with 
active telomerase (Figure 8) (Forsythe, et al., 2001). This association has been identified in 
prostate cancer with increasing levels of chaperone proteins correlating with cancer progression 
(Alkalin, et al., 2001).  
 
Hsp90 inhibitors 
Various drugs have been developed to target Hsp90 and other chaperones by inhibiting 
the ability of chaperones to maintain their activation-competent conformation, resulting in the 
client proteins’ degradation (Schulte, et al., 1997). For example, 17-AAG binds to the complexed  
tumor specific form of Hsp90 (Kamal, et al., 2003), thus inhibiting Hsp90 and inducing 
apoptosis (Sreedhar and Csernaly, 2004).   
Two natural product inhibitors of Hsp90, geldanamycin and Radicicol, are used in both 
the laboratory and in clinical trials. Originally identified as an antimicrobial agent, geldanamycin 
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(GA) is in the ansamycin family (DeBoer, et al., 1970). GA has antiproliferative activity in a 
range of tumor lines and reversibly binds the N-terminal ATP binding site of Hsp90 (Whitesell, 
et al., 1994) to inhibit the ATPase activity of Hsp90 (Figure 9) (Prodromou, et al., 1997).  In 
vivo, geldanamycin treatment leads to hepatotoxicity (Supko, et al., 1995), requiring the 
development of various, more tolerable, analogs. The most successful is 17-allylamino 17-
demethoxy geldanamycin (17-AAG), which has decreased hepatotoxicity and increased Hsp90 
inhibitory actions (Schnur, et al., 1995). 17-AAG still exhibits solubility problems, whereas the 
analog 17-DMAG (17-NN-Dimethyl-Ethylene Diamine-Geldanamycin) may be used as an oral 
drug (Tian, et al., 2004; Jez, et al., 2003).  
Radicicol (RAD) was originally isolated as an antifungal antibiotic (Delmotte and 
Delmotte-Plaque, 1953). Radicicol also acts on Hsp90 by binding the N-terminus and inhibiting 
its ATPase activity and is able to act in an antitumorigenic mechanism by preventing Hsp90 
from folding client proteins (Figure 9) (Schulte, et al., 1998). Radicicol is less cytotoxic than 
geldanamycin but does not contain the same tumor-cell specificity or solubility. In vivo studies 
have not resulted in significant antitumor activity (Geneg, et al., 2004). However, the similarity 
to geldanamycin in its actions on Hsp90 and its similar effects at lower concentrations make it 
ideal for use in the laboratory. 17-AAG has completed Phase I testing as a single agent and is 
now in tumor specific Phase II trials and combination Phase I trials for breast and prostate 
tumors (Jameel, et al., 1992). Hsp90 makes an attractive anti-cancer drug target for a variety of 
reasons: mutant proteins rely on Hsp90 for stabilization and prevention of degradation, and it has 
the potential to inhibit all six hallmarks of cancer through its client proteins. Those hallmarks 
(and examples of Hsp90 client proteins) are: ability to evade apoptosis (Survivin), angiogenesis 
(VEGF, VEGFR, and HIF1), immortalization (hTERT), tissue invasion and metastasis (MET  
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Figure 9. Hsp90 inhibitors. Inhibitors such as geldanamycin, 17-AAG, and Radicicol reversibly 
bind the N-terminal ATP binding site of Hsp90 and inhibit the ATPase activity of Hsp90 
resulting in cell death. These inhibitors also prevent Hsp90 from releasing its client protein, thus 
targeting the protein for degradation. Adapted from: Schulte, et al., 1997. 
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and MMP2), insensitivity to anti-growth signals (CDK4), and self-sufficiency in growth signals 
(RAF and ErbB2) (Hanahan and Weinberg, 2000; Kamal, et al., 2003). In human tumor 
xenograft models, the complexed form of Hsp90 is more sensitive and has a greater affinity for 
specific inhibitors due to higher ATPase activity (Kamal, et al., 2003). Therefore, 17-AAG 
accumulates in cancer cells specifically and synergizes with other cancer therapies. Hsp90 
inhibitors attack multiple oncogenic pathways and prevent activation of alternative pathways, 
thereby preventing drug resistance (Jameel, et al., 1994).  
 
Hsp70 
Hsp70 is a ubiquitous 70-kDa heat shock protein with multiple chaperoning activities 
including folding and assembly of nascent proteins, refolding of aggregated proteins, and cellular 
localization through interaction with client proteins in an ATP-dependent manner (Ryan and 
Pfanner, 2002; Pratt and Toft, 2003; Bukau, et al., 2000; Hartl and Hayer-Hartl, 2002). Hsp70 is 
found to be required for assembly of active telomerase (Holt, et al., 1999). Along with Hsp90, 
Hsp70 is upregulated in cancer (Ricaniadis, et al., 2001). Mice with heat-inducible Hsp70 
knocked out (Hsp70.1/3-/-) displayed a higher rate of spontaneous genomic instability, with a 
noticeable effect on telomere stability. This suggests that Hsp70 not only plays a role in 
telomerase activity but also suppresses tumor formation with activity at the telomere (Hunt, et al. 
2004).  
 
Co-Chaperone, p23 
Initially, p23 was identified as a ubiquitous protein complexed with Hsp90 and Hsp70 in 
avian progesterone receptors and was found to be a highly conserved acidic phosphoprotein 
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containing an aspartic acid-rich C-terminal domain (Johnson, et al., 1994; Johnson and Toft, 
1995; Johnson, et al., 1996). As a co-chaperone of Hsp90, p23 binds to the ATP bound dimeric 
Hsp90 and stabilizes it in its ATP-hydrolyzed state (Richter, et al., 2004; Sullivan, et al., 2002; 
McLaughlin, et al., 2002; Pratt and Toft, 1997). In steroid receptors, p23 increases the number of 
complexes that can bind to the hormone, again likely through stabilization of Hsp90 (Grenert, et 
al., 1999; Young and Hartl, 2000). It has passive chaperoning activities of its own, suppressing 
aggregation of heat denatured citrate synthase and β-galactosidase (Bose, et al., 1996; Freeman, 
et al., 1996). Along with Hsp90, p23 is required to activate telomerase in vitro and remains 
stably associated with active telomerase (Holt, et al., 1999; Forsythe, et al., 2001). The yeast p23 
ortholog, Sba1p, and the ortholog for Hsp90, Hsp82p, can modulate telomerase’s ability to bind 
telomeric DNA both in vitro and in vivo, as well as being required for telomerase-mediated 
telomere extension in yeast (Toogun, et al., 2007; Forafonov, et al., 2008). Inhibition of Hsp90 
also inhibits telomerase activity, suggesting that a fully functional Hsp90-p23 bound hTERT is 
required for telomerase to become active and extend telomeres (Keppler, et al., 2006). Further 
roles of the Hsp90 complex (including p23 and Hsp70) in telomere biology have yet to be 
elucidated. Therefore, identification of chaperones at the telomere independent of telomerase, 
perhaps through interactions with other telomeric proteins, opens a new path to understanding 
telomere biology as well as possibly providing additional cancer targets through chaperone 
inhibition. 
 
STUDY RATIONALE 
The literature, along with work from our lab, suggests that the chaperones play a major 
role in telomere length regulation through their association with telomerase (Holt, et al., 1999; 
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Akalin, et al., 2001; Forsythe, et al., 2001; Compton, et al., 2006). However, there is no 
literature addressing further actions of the chaperones on the telomere independent of 
telomerase. Our identification of Hsp90, Hsp70 and p23’s interactions with telomeric proteins 
reveals novel associations that may have significant implications in telomere biology. The 
interactions between Hsp90 and TRF2 and TRF1 are especially interesting, as both TRF1 and 
TRF2 are imperative for proper telomere maintenance. The focus of this work was to determine 
the mechanism of chaperone regulation on telomeres and the functional significance of the 
interactions of chaperones with telomere-associated proteins. In addition, a determination of the 
effects of chaperone down-regulation (pharmacologically) on telomeres was studied.  Much has 
been studied in regards to telomeric protein-protein interactions and protein-DNA binding (rev. 
in Karlseder, et al., 2003). It is possible that the chaperones facilitate these interactions, as they 
are known to have roles in protein-protein interactions and DNA binding (rev. in Hartl, 1996). 
Our specific aims were to 1) identify the interaction of chaperones Hsp90, Hsp70 and p23 with 
telomeric proteins TRF2, TRF1, TIN2 and TPP1 and 2) determine the functional significance of 
these interactions through pharmacologic inhibition of Hsp90. Our data indicates that Hsp90 
does, in fact, associate with the telomere independent of telomerase, through novel interactions 
with the telomere binding proteins TRF2, TRF1, TIN2 and TPP1. To elucidate the mechanism 
for the interactions, we inhibited Hsp90 with compounds currently in clinical trials for breast 
cancer and examined the effects on telomere/protein binding, protein/protein interactions, protein 
degradation, and telomere dysfunction. The chaperone/telomere protein interactions may provide 
further understanding of telomere proteins and telomere protection, although this is beyond the 
scope of this study. 
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Chapter 2 
Materials and Methods 
 
Cell Culture  
MCF7, a human breast cancer cell line, expressing ectopic hTERT was created as 
described previously (Elmore, et al., 2002). MCF-7 cells were cultured using RPMI 1640 
containing 5% fetal bovine serum and supplemented with gentamicin (0.05 mg/ml) grown at 
37°C in 5% CO2. H1299, a human lung carcinoma cell line, was cultured using DMEM 
containing 5% cosmic calf serum and supplemented with gentamicin (0.05mg/ml) grown at 37°C 
in 5% CO2.  
 
Reagents 
Antibodies used include: anti-mouse Hsp90, anti-mouse Hsp70, and anti-mouse p23 
(from Dr. David Toft, Mayo Clinic, Rochester, MN), anti-mouse Hsp90 (Stressgen, Ann Arbor, 
Michigan), anti-rabbit TRF2 (Imgenex, San Diego, CA), anti-rabbit TRF1 and anti-rabbit 
Ubiquitin (Santa Cruz Biotechnology, Inc, Santa Cruz, CA), anti-mouse hTERT (Rockland, 
Gilbertsville, PA), anti-rabbit Pan-Sumo, anti-rabbit SUMO1, anti-rabbit SUMO2 (Abgent, San 
Diego, CA) and anti-mouse IgG (Sigma, St. Louis, MO).  
 
Chromatin Immunoprecipitation 
For ChIP, cells were grown to approximately 90% confluency and fixed with 1% 
formaldehyde directly on the plate. Glycine was added to a final concentration of 0.125M to 
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remove excess formaldehyde. Following a PBS wash, cells were resuspended in lysis buffer 
(5mM PIPES pH 8.0, 85mM KCl, 0.5% NP-40, 1mM PMSF, 1X protease inhibitors), incubated 
on ice and lysed by dounce homogenization. Nuclei were then lysed (50mM Tris pH 8.1, 10mM 
EDTA, 1% SDS, 1X protease inhibitors) and sonicated to ~1000 bp fragments using a Missonex 
3000 sonciator with microtip. The sheared DNA was diluted 3:1 in 0.01% SDS, 1.1% Triton X-
100, 1.2mM EDTA, 16.7mM Tris-HCl, pH 8.1, 167mM NaCl. After preclearing with 25% 
salmon sperm DNA/Protein A/G, the supernatants were equally divided and immunoprecipitated 
overnight at 4°C with antibodies directed against Hsp90 (1µg/ml), Hsp70 (1µg/ml), or p23 
(1µg/ml), TRF2 (5µg/ml), hTERT (5µg/ml), IgG (0.5µg/ml) and TRF1 (5µg/ml). 
Immunocomplexes were recovered with a Protein A/G slurry and washed sequentially in Low 
Salt Immune Complex Wash (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 
8.1, 150mM NaCl), High Salt Immune Complex Wash (0.1% SDS, 1% Triton X-100, 2mM 
EDTA, 20mM Tris-HCl pH 8.1, 500mM NaCl), LiCl Immune Complex Wash (0.25M LiCl, 1% 
NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl pH 8.1) and 1X TE buffer (10mM Tris-
HCl, 1mM EDTA pH 8.0). Immune complexes were eluted with 1% SDS, 0.1M NaHCO3. 
Crosslinks were reversed by overnight incubation in a 5M NaCl solution at 80°C. At the 
completion of this incubation, Proteinase K was added to the eluate in 0.5M EDTA and 1M Tris 
pH 6.5 at 45°C for 1h. DNA was then precipitated with ethanol, and the pellets resuspended in 
dH2O. DNA samples were applied to a slot blot apparatus with a nylon membrane. The 
membrane was then processed and probed for a telomeric signal using a radiolabeled telomeric 
primer, as described previously (Elmore, et al., 2002). 
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Transcription/Translation 
TRF2 was synthesized in the RRL system (TNT, Promega) as described previously (Holt, 
et al., 1999) in the presence of [35S] methionine. A total of 1µg of plasmid DNA was used for 
each TnT reaction. The WT TRF2 plasmids were a gift from Dr. Dominique Broccoli (Memorial 
University Medical Center, Savannah GA).  
 
Drug Treatments 
Radicicol was tested at varying concentrations (Sigma, St. Louis, MO) and MG132 at 
10µM (Sigma, St. Louis, MO) both solubilized in DMSO (control). In vitro, TnT lysates were 
treated with 50µg/ml Radicicol or Geldanamycin at 30°C for 90 minutes. Cell cultures were 
treated with 0.1µM or 0.3µM Radicicol for specified times at 37°C.  
 
Growth Assay 
H1299 cells were plated 100,000 cells/well in a 6-well dish. At 6 hours after plating, cells 
were treated with varying concentrations of Radicicol (0.03µM, 0.1µM, 0.3µM, 1µM, and 3µM, 
as well as DMSO vehicle treated). Drug was replaced every 48 hours. Cells from triplicate 
cultures were trypsinized and counted using a hemocytometer at 24 hrs, 72 hrs, and 120 hours 
and presented as total cell numbers. 
 
Cell Extracts 
For whole cell extracts, cells were pelleted and resuspended in Modified RIPA buffer (50 
mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.25% sodium-deoxycholate, 1mM EDTA) plus 
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1 mM protease inhibitor cocktail (Calbiotech). Cells were lysed by sonication on ice at 60% 
power for 10 seconds four times using a Missonex 3000 sonciator with microtip.  For nuclear 
extracts, nuclei were isolated using the Cell Lytic NuCLEAR Extraction kit without detergent 
(Sigma Chemical Companies). The cells were lysed in a hypotonic lysis buffer and dounce 
homogenized. The extraction buffer was diluted for a final NaCl concentration of 150mM with 
1X Dilution and Equilibration Buffer to ensure sufficient lysis of the nuclei without disruption of 
interactions. 
 
Immunoprecipitation 
For immunoprecipitations from in vitro assembly reactions, Hsp90, Hsp70, p23, TRF2 
and IgG (antibodies at 1µg/ml) antibodies were added to a 50/50 mixture of Protein A/G beads 
(Roche) and incubated on ice for two hours. Lysates from the TRF2 TnT reaction were then 
added to the antigen/bead complex and incubated at 4°C rotating overnight. Beads were then 
pelleted and washed four times in CHAPS lysis buffer (19mM Tris-HCl pH7.5, 1mM MgCl2, 
0.1mM Benzamidine, 1mM EGTA, 5mM β-mercaptoethanol, 0.5% CHAPS, 10% glycerol). 
  For immunoprecipitation reactions from nuclear and whole cell extractions, antibodies 
Hsp90 (0.5µg/ml), Hsp70 (0.5µg/ml), p23 (0.5µg/ml), TRF2 (1µg/ml), hTERT (1µg/ml), 
Ubiquitin (1µg/ml) and SUMO1/2 or Pan-SUMO (1µg/ml) were added to corresponding samples 
and incubated on ice two hours. Prewashed Protein A/G beads were then added to the samples 
and incubated overnight 4°C, with continual agitation. Following the incubation, beads were 
pelleted and washed three times with CHAPS lysis buffer.  
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Gel Electrophoresis and Imaging 
For both immunoprecipitations from TnT reactions and nuclear extractions, Laemmli 
buffer was added to beads, which were then heat denatured at 95°C for 10 minutes. Samples 
were separated by SDS-PAGE. For the nuclear extractions, following the electrotransfer of 
proteins onto Hybond nitrocellulose membranes (Amersham, Arlington Heights, IL), a standard 
Western blotting protocol was performed (Elmore, et al., 2002). For TNT reactions, after 
samples were run on SDS-PAGE, the gel was fixed in a 10:20:70 solution of glacial acetic 
acid:methanol:water. The gel was then dried and exposed to a phosphoimager. Images were 
visualized using the PhosphoImager (Molecular Dynamics, Sunnyvale, CA) or the Typhoon 
Variable Mode Imager (GE Healthcare Life Sciences, Piscataway, NJ) and ImageQuant (GE 
Healthcare Life Sciences, Piscataway, NJ) image analysis software. Densitometry was performed 
using the ChemiImager software (Alpha Innotech, San Leandro, CA).
 
Immunofluorescence 
Cells were plated on alcohol, heat-treated cover slips (22mm) in a 6-well dish and grown 
to approximately 70% confluency. Cells were then treated with 0.3µM Radicicol for 1, 2, 4, 6, 8 
and 16 hrs as indicated. Following the appropriate incubation, the cells on the cover slips were 
fixed with 3.7% paraformaldehyde in 1X PBS, washed with 1X PBS and permeabilized with 
0.5% NP-40 in 1X PBS, and washed with 1X PBS. Cover slips were then blocked with PBG 
buffer (0.2% cold water fish gelatin, 0.5% BSA in 1X PBS), and incubated in rTRF2, rTRF1 
(5µg/ml in PBG) or mHsp90 (0.5µg/ml in PBG) antibody at 4°C overnight. Cover slips were 
washed in 1X PBS and then incubated with either Alexa 568 anti-rabbit or Alexa 488 anti-mouse 
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secondary antibody (Invitrogen, Carlsbad, CA). Cover slips were washed with 1X PBS, and 
stained with 4’6-diamidino-2-phenylindole (DAPI) followed by mounting in Vectashield (Vector 
Lab). Secondary antibody only cover slips served as negative controls. Representative images 
were captured using either a Nikon Eclipse E800M fluorescence microscope or a Leica TCS-SP2 
AOBS confocal laser scanning microscope. Images were analyzed using the Leica LCS Lite 
masked cytofluorogram confocal software. 
 
Statistical Analysis 
 Densitometry was performed using the ChemiImager software (Alpha Innotech, 
San Leandro, CA). For in vitro immunoprecipitations, western blots, and immunofluorescence 
analyses, a Duncan’s new multiple range test was performed to assess statistical significance of 
mean sample differences with significance set at p<0.05 from three independent experiments. 
For in vitro Immunoprecipitation to compare drug treatments, ANOVA was performed with 
significance set at F<0.05. 
 
Telomere Length Analysis 
Telomere length was determined using the terminal restriction fragment (TRF) length 
assay as described previously (Elmore, et al., 2002). Briefly, DNA was isolated from cells using 
genomic tips (Qiagen). A total of 7µg of genomic DNA was digested with a cocktail of 
restriction enzymes (AluI, HaeIII, HinfI, MspI, and RsaI, New England Biolabs) and resolved on 
a 0.7% agarose gel. A G-rich telomeric probe [(TTAGGG)4] was labeled through random 
priming with [γ-32P]ATP (6000 Ci/mmol), with unincorporated nucleotides being removed 
using aQIAquick nucleotide removal kit, according to manufacturer’s protocol (Qiagen). The gel 
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was dried and hybridized with the radiolabeled G-rich probe for 12-16 hours. Following washing 
to remove unbound probe, the gel was exposed to a PhosphorImager cassette overnight 
(Molecular Dynamics). 
 
Cytogenetics 
To determine if telomeric sequences were involved in end-to-end fusions, metaphase 
spreads from H1299 cells were scored following fluorescence in-situ hybridization (FISH) using 
a pantelomeric peptide nucleic acid probe (PNA). The metaphase spreads from the treated (1 
day; 3 days; and 5 days chronic exposure to a 0.3µM solution of Radicicol) and control 
(untreated) cultures were harvested using standard procedures (Rooney and Czepulkowski, 
1992). Briefly, actively dividing cells were blocked in mitosis through a 1 hour exposure to 
0.1µg/ml of colcemid.  Following lifting (using trypsin), the cells were incubated in a hypotonic 
solution (0.075M KCl at 37ºC for 20 minutes). The cells were then fixed, using serial room 
temperature incubations, in Carnoy’s fixative (3 parts methanol to 1 part acetic acid) and slides 
made using standard procedures. The FISH was performed using a synthetic pantelomeric probe 
following the manufacturer’s protocol (DAKO). Briefly, after fixation, pre-treatment, and 
dehydration, the metaphase chromosomes and FITC-labeled probe [(C3TA2)3] were co-denatured 
(5 min at 80°C). Following hybridization (30 minutes at room temperature), the excess, unbound 
probe was removed by washing (65°C for 5 minutes with agitation). The slides were then 
dehydrated with cold ethanol, air dried, and counterstained with a DAPI/Antifade solution 
(Cytocell).  
The presence or absence of telomeric signals or end-to-end chromosomal fusions was 
scored using a Zeiss Axioskop, with representative images being captured using a Cytovision 
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image analysis system (Applied Imaging). The frequency of chromosomal findings present in the 
cell treatments and control cultures were compared using a Chi-square goodness of fit test, with 
an α level of 0.05. 
 
Prediction of SUMOylation sites 
Potential TRF2 SUMOylation sites were identified using the Abgent SUMOPLOT 
program (Abgent, San Diego, CA). 
 
In vitro SUMOylation assay 
Using the Vaxron In Vitro SUMOylation Assay kit (Vaxron, Rockaway, NJ) TRF2 or 
dnTRF2 was synthesized using the RRL system and radiolabeled with 35S (TNT, Promega). A 
10X Reaction Buffer (0.2M Hepes-NaOH, pH 7.4, 50mM MgCl2, 20mM ATP, 0.5mM PMSF, 
1mg/ml BSA), SUMO-1 (1mg/ml), GST-Ubc9 (0.4mg/ml), and SAE1/2 (1 unit/µl) from the kit 
were then added to the TnT lysates (10µl), which were incubated at 37°C for 120 minutes.  
Samples were separated on an SDS-PAGE gel and exposed to a PhosphorImager cassette 
overnight (Molecular Dynamics). 
 
Site-Directed mutagenesis 
Mutations were created using the QuikChangeII Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA). For single mutant strand synthesis K150R, the primers used were 
KR150TRF2S (GTGCTGGAGATGATTAGAACGGAATTTACAACTGACAGAAGC 
AGTGG) and KR150TRF2AS (CCACTGCTTCTGTCAGTGTAAATTCCGTTCTA 
ATCATCTCCAGCAC). For the K255R mutation, primer KR255TRF2S (CGATGG 
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CCAAAAAGGCTTTGAGATCTGAGTCCGCTGCC) and KR255TRF2AS (GGCA 
GCGGACTCAGCATCTCAAAGCCTTTTTGGCCATCG) were used. A final concentration of 
10ng of pcDNA3TRF2full dsDNA was added to the PCR reaction (125ng S and AS primer, 10x 
PCR buffer, dNTP, 5% DMSO and 1µl PfuUltra HF DNA Polymerase; cycling conditions: 95ºC 
30 sec, 18 cycles 95ºC 30 seconds, 55ºC 1 minute, 68ºC 7 minutes). The reaction was then 
digested for 1 hour at 37ºC with 1µl DpnI (10 units/µl) enzyme, transformed into DH5α 
competent cells (Bioline, Taunton, MA), and screened by sequence analysis across the mutation 
region. A single positive clone was sequence verified across the entire insert region. For the 
double mutant, K150R was used as a template for the K150R/K255R double mutation. Reaction 
and verification were performed as above, with DpnI digestion, transformation and sequence 
analysis.  
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Chapter 3 
Chaperone-mediated Regulation of Telomere Associated Proteins 
 
INTRODUCTION 
The telomeric multiprotein complex organizes the linear chromosome end into a t-loop 
structure, which contributes to telomere length regulation and end protection (Griffith, et al., 
1999). The t-loop prevents the telomere from being recognized as damaged DNA and from 
cellular exonucleases acting on the telomere (Griffith, et al., 1999). One protein in particular, 
TRF2, aids in protection of telomeres from end-end fusions by directing the invasion of the 3’ 
single strand overhang into duplex telomeric DNA, creating the t-loop (Griffith, et al., 1999; 
Stansel, et al., 2001). TRF1 is another protective telomere binding protein that coats the double 
stranded telomeric DNA and aids in formation of the t-loop. In addition to the structural function 
of TRF1 at the telomere, its main role in telomere length homeostasis has been reported to be 
preventing telomerase access in normal cells (Smorgorzewska, et al., 2000). As a second major 
player in protection of the telomere, it is imperative to understand TRF1’s regulation and post-
translation modifications, as well as TRF2. 
Heat shock proteins (Hsps), or chaperones, are ubiquitous proteins required for cell 
processes including folding of the nascent polypeptide chains, preventing protein aggregation, 
and transporting proteins across the membrane (Hartl, et al., 1996). In tumor cells, chaperone 
expression is often increased, presumably to maintain homeostasis and to allow tumor cells to 
tolerate microenvironment alterations, which results in normally lethal mutations enhancing 
oncogenesis (Sausville, et al., 2003). One specific chaperone involved in this process is Hsp90, 
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which is over-expressed in breast cancer (along with Hsp70) and correlates with a poor prognosis 
(Grem, et al., 2005), making it a potential target for therapeutic treatment of cancer. 
We hypothesized that the interaction of chaperones and telomere proteins occurs as a 
means for Hsp90 to target TRF1 and TRF2 for degradation.  Hsp90 acts on mutated proteins in 
tumor cells to target them for degradation, and because many proteins bound to the telomere also 
tend to be altered in tumor cells (either from critically short telomeres or 
deregulation/modification), it is likely that Hsp90 is targeting telomere-associated proteins for 
ubiquitination as well. The specific aims of this study were to attempt to define the role of 
chaperones at the telomere by first defining the interactions between Hsp90 and the telomeric 
proteins TRF1 and TRF2 through Co-IP/Western and then determining the functional 
significance of the interactions through pharmacologic inhibition of Hsp90 using Co-IP/Western 
and colocalization studies. e of the interaction at the present time, however further studies are 
being conducted/ 
Chaperones Bind to the Telomere 
Previous studies have demonstrated that Hsp90 associates with the telomere through a 
direct interaction with hTERT (Holt, et al., 1999; Forsythe, et al., 2001). We hypothesized that 
Hsp90 and perhaps other components of the Hsp90 chaperone complex are present at the 
telomere independent of telomerase. To determine if chaperones bind the telomere, a chromatin 
immunoprecipitation (ChIP) assay was performed. We used H1299 lung carcinoma cells, which 
have naturally long telomeres (approximately 25 kb), providing plenty of substrate. In addition to 
H1299 cells, MCF7 breast carcinoma cells and normal BJ foreskin fibroblast cells, both 
ectopically overexpressing hTERT, were used because expression of hTERT elongates 
telomeres, providing more substrate for telomere associated proteins to bind and thus increasing 
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the sensitivity and detection of these associations. As it is difficult to design PCR primers for 
telomeric repeat sequences, we radiolabeled a telomere sequence specific probe to visualize 
telomeric DNA binding of our immunoprecipitated fragments. Positive signal in the Chromatin 
Immunoprecipitation assay (ChIP) indicates that a specific protein was bound directly to 
telomeric DNA. TRF1 and TRF2 serve as positive controls as they are known to bind directly to 
the telomere. IgG serves as a negative control. We show that Hsp90 and Hsp70 bind to telomeres 
in the cancer cell lines H1299 and MCF7 hTERT (Figure 10A and 10B). The normal BJ-hTERT 
foreskin fibroblast cells also demonstrate that the chaperone Hsp70 was found at the telomeres in 
normal cell lines (Figure 10C). Interestingly, we only detect telomeric p23 above background 
IgG levels in the BJ-hTERT cells (Figure 10C) and not in the H1299 or MCF7 cells (Figure 10A 
and 10B), which may be due to p23’s association with Hsp90 and indirect association with 
telomeric proteins in cancer cells. Previous studies from our laboratory indicate that Hsp90 and 
p23 remain stably associated with the telomerase enzyme (Forsythe, et al., 2001), indicating that 
a subfraction of these chaperones are likely associated with hTERT at the telomere. However, 
based on the amount of Hsp90 and Hsp70 (each at 1µg/ml)  bound at the telomere (Figure 10A-
10C), their association is likely, at least in part, independent of hTERT. In the H1299 cells, 
hTERT was present at similar levels to all other proteins, likely due to the increased amount of 
telomere substrate (Figure 10A).  
 
Interaction of Telomere Associated Proteins and Chaperones 
Since a subfraction of Hsp90 binds to the telomere, possibly independent of hTERT, we 
hypothesized that components of the Hsp90 chaperone complex associate with telomere proteins, 
including TRF1 and TRF2. The rabbit reticulocyte lysate (RRL) transcription and translation  
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Figure 10. Chaperones are present at telomeres. Using chromatin immunoprecipitation and a 
telomeric probe, antibodies for the indicated proteins were used to determine if there was an 
interaction with telomere sequences. A. H1299 cells. IgG serves as a negative control. Input is 
1% sheared DNA and serves as the positive control for hybridization. TRF1 and TRF2 serve as 
positive controls, since they are known to bind directly to the telomere (Broccoli, et al., 1997) B. 
MCF7 cells overexpressing hTERT and C. BJ-hTERT fibroblast cells. The chaperones and 
telomeric proteins are bound to the telomeric DNA in all three cell lines. 
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(TnT) system is ideal for identifying interactions with chaperone proteins, as there is an 
abundance of chaperone proteins in the reticulocyte lysate. When the protein of interest, such as 
TRF2, is synthesized, it is the only radiolabeled protein present in the system to interact with the 
chaperones. Using this TnT system, we can therefore determine if TRF2 directly interacts with 
the chaperone proteins independent of any other protein in the cell. Thus, TRF2 was radiolabeled 
and synthesized in vitro, and the resulting lysate was immunoprecipitated for Hsp90, Hsp70 and 
p23. When the immunoprecipitates were visualized using an SDS-PAGE gel, positive bands for 
TRF2 indicated a direct interaction with Hsp90, Hsp70, and p23 in vitro (Figure 11).  
To further explore the hypothesis that Hsp90 interacts with telomeric proteins, we 
extended our studies to co-immunoprecipitation (Co-IP) in cultured MCF7-hTERT cells and 
H1299 cells to assess whether the in vitro interaction between telomeric proteins and Hsp90 
exists in tumor cells. To ensure specificity and increase sensitivity in our cell studies, all 
subsequent studies were done using nuclear extracts (unless otherwise indicated). Hsp90 is 
primarily an abundant cytoplasmic protein making up 1-2% of total cytoplasmic protein while 
telomeric proteins are strictly nuclear (Lai, et al., 1984). Therefore, nuclear extracts increase the 
likelihood that the interaction between TRF2 and Hsp90 is a real interaction and not an artifact of 
cytoplasmic Hsp90 contamination. Figure 12A suggests a high purity of our nuclear extraction, 
through Western blot showing Histone H1, a nuclear protein, present only in nuclear extract 
lysates. Co-IP/Western blots show that both  TRF2 and TRF1 interact with Hsp90 and Hsp70 in 
the H1299 cell line (Figure 12B and 12C, respectively) and TRF2 interacts with Hsp90 and 
Hsp70 in the MCF7-hTERT cell line (Figure 13A and 13B). There was no detectable p23/TRF2 
interaction in MCF7-hTERT or H1299 cells as was seen in vitro, which may suggest that p23 is 
associating with TRF2 through other telomere binding or chaperone proteins.  
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Figure 11. In vitro interaction of TRF2 with chaperones.  Immunoprecipitation was 
performed using antibodies against TRF2, Hsp90, Hsp70, and p23 after expression of 35S-
methionine labeled TRF2 in the TnT system. A positive interaction result shows precipitation of 
the radiolabeled TRF2. 5µl lysate was loaded as a positive control, and IgG serves as a negative 
control.  
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Figure 12. Interaction of telomeric proteins with chaperones from H1299 cells. A. 
Verification of nuclear extracts. Cells were lysed, and nuclear and cytoplasmic fractions were 
isolated. A Western blot using 20µg of protein from each extract of two separate samples was 
probed for the nuclear protein, Histone H1, which runs at 32 kDa. B. TRF2 was 
immunoprecipitated from nuclear extracts and a Western blot was probed for Hsp90, Hsp70 and 
TRF2. Protein G agarose beads only serve as a negative control. C. Western analysis of 
immunoprecipitations of the telomere binding protein TRF1 was accomplished using 
chaperone, TRF1 and IgG antibodies. TRF1, Hsp90 and IgG were immunoprecipitated from 
nuclear extracts as indicated and a Western blot was probed for Hsp90 and Hsp70. IgG serves 
as a negative control. D. Western analysis of immunoprecipitations of telomere-associated 
proteins was accomplished using chaperone, TIN2, TPP1 and IgG antibodies. TIN2 and TPP1 
were immunoprecipitated from nuclear extracts and a Western blot was probed for Hsp90 and 
Hsp70. IgG serves as a negative control. 
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Figure 13. Interaction of TRF2 with chaperones from MCF7-hTERT cells. A. Western 
analysis of immunoprecipitations of telomere-associated proteins was accomplished using 
Hsp90, TRF2 and IgG antibodies. TRF2 and Hsp90 were immunoprecipitated from nuclear 
extracts and a Western blot was probed for Hsp90. IgG serves as a negative control (left panel). 
TRF2 and hTERT were immunoprecipitated and a Western blot was probed for Hsp90 and 
Hsp70. hTERT serves as a positive control for immunoprecipitation and Western blot because of 
its known interaction with Hsp90 (right panel). IgG Heavy Chain (HC) serves as antibody 
controls and are visualized when the primary and secondary antibodies are derived from the 
same species. B. Hsp90 Western blot after immunoprecipitation with Hsp90, Hsp70 and TRF2. 
Hsp90 and Hsp70 are known to interact, and an interaction between Hsp90 and TRF2 was 
observed.  
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The interaction between TRF2, TRF1 and Hsp90/Hsp70 led us to hypothesize that Hsp90 
and Hsp70 were also interacting with other telomere associated proteins, such as TPP1 and 
TIN2. TIN2 is one of the six Shelterin proteins and forms a “bridge” between TRF2 and TRF1 
(Ye, et al., 2004) and interacts directly with TRF1, mediating its activity and acting as a negative 
regulator of telomere elongation (Kim, et al., 1999). Another member of the Shelterin complex, 
TPP1, binds POT1 and directly interacts with TIN2 (Ye, et al., 2004). A Co-IP/Western of TIN2 
and TPP1 probed for Hsp90 and Hsp70 verifies that both proteins interact with both chaperones 
in H1299 cells (Figure 12D), although the association with Hsp70 for both TIN2 and TPP1 is 
fairly weak.  
Through Co-IP/Western we have identified novel interactions of the telomeric proteins 
TRF1, TRF2, TIN2 and TPP1 with the chaperones Hsp90 and Hsp70. These interactions suggest 
that the chaperones may be contributing some regulatory function on telomeric proteins such as 
mediating protein-protein interactions of telomeric proteins or facilitating association with the 
telomere.  
Inhibition of Hsp90 
 The interaction between TRF2/TRF1 and the Hsp90 chaperone suggests a functional 
relationship between the proteins. We hypothesized that inhibition of Hsp90 would result in a 
disruption in TRF1/2’s ability to bind to the telomere resulting in degradation of each protein, 
thereby disrupting their protective function at the telomere. Inhibitors of Hsp90 are currently 
used in breast cancer therapy, notably 17-AAG (an analog to Geldanamycin), which is in Phase 
II clinical trials (Banjeri, et al., 2005; Goetz, et al., 2005; Grem, et al., 2005). We used both 
Geldanamycin (GA) and Radicicol (RAD) in in vitro experiments and RAD in cell culture 
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experiments to determine if inhibition of Hsp90 affects its interaction with TRF2 and TRF1, as 
well as their function at the telomere. We used the RRL system to synthesize TRF2 or TRF1 in 
vitro and then added 50 µg/ml of Radicicol, Geldanamycin or equivalent volumes of DMSO as 
the untreated sample and performed an assembly reaction at 30°C for 90 minutes. The 
TRF2/TRF1 that was assembled in presence of drug was immunoprecipitated with antibodies 
against Hsp90, TRF2, or TRF1 (Figure 14A and C). We first performed an ANOVA to 
determine if there was a significant difference between the effects of the two drugs. There was 
no significant difference when RAD is compared to GA for each immunoprecipitation (F>0.05). 
However, using the Duncan’s new multiple range test to compare each drug treatment for each 
IP, the Hsp90/TRF2 interaction, when treated with either RAD or GA, is significantly disrupted 
when compared to the DMSO control for RAD only (p<0.05) (Figure 14B). Thus, although there 
is no difference in disruption of interaction between the two drugs, there is a difference between 
RAD and untreated. For this reason and reduced cellular toxicity, we continued using RAD 
rather than GA in subsequent cell based experiments.  
A growth curve was performed to determine the optimal RAD concentration to use in our 
experiments. 0.3µM RAD had an effect on cell count without causing total cell death at five 
days. At 1µM and higher, cells began to die at day 3, and at 0.1µM and lower, minimal effect 
was observed (Figure 15). Therefore, 0.3µM RAD was used in subsequent experiments.  
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Figure 14. Hsp90 inhibition affects TRF2/Hsp90 interaction. A. TRF2 was synthesized in 
vitro and then 50µg/ml Radicicol, Geldanamycin, or DMSO was added to the synthesized TRF2 
assembly reaction. Samples were then immunoprecipitated for Hsp90 or TRF2. 3µl of 
synthesized TRF2-TnT was run as a positive control. B. IDV (integrated density values) were 
normalized to untreated samples (value = 1) for each immunoprecipitation. Duncan’s new 
multiple range test suggests a significant difference between the Hsp90/TRF2 interaction when 
treated with RAD compared to untreated from three independent experiments (p<0.05). C. TRF1 
was synthesized in vitro and then 50µg/ml Radicicol, Geldanamycin, or DMSO was added to the 
synthesized TRF1 assembly reaction. Samples were then immunoprecipitated for Hsp90,and 
TRF1. The greatest interference in the Hsp90/TRF1 interaction was seen with Radicicol 
treatment as identified through quantitation with densitometry (see outlined box) from one 
experiment. IDV (integrated density values) were normalized to untreated samples for each IP 
(value = 1). 3µl of synthesized TRF1-TnT was run as a positive control. 
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Figure 15. Growth curve of H1299 cells after Radicicol treatment. Cells were treated with 
varying concentrations over 7 days to determine optimal drug treatment concentration. 0.3µM 
was used in subsequent experiments, as it had an effect on cell growth without causing total cell 
death by day 5. 
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                 We hypothesized that inhibition of Hsp90 would affect the binding of telomeric 
proteins and chaperones to the telomere. To explore this, H1299 cells were chronically treated 
for 2, 4 and 8 hours with the Hsp90 inhibitor Radicicol (RAD) at 0.3µM (Figure 16A). 
Quantitation by densitometry of telomere binding by ChIP showed an increase in binding of the 
telomere proteins TRF1, TRF2, TIN2 and TPP1 after 2 hours of treatment (Figure 16B), 
suggesting that early inhibition of Hsp90 may allow telomere binding proteins more access to the 
telomere. It may also suggest that in untreated cells, Hsp90 forms a bridge between the telomeres 
for stability, which is eliminated with inhibition of Hsp90 causing telomeric proteins to bind the 
telomere more tightly.  This increased binding is reduced by 8 hours, as expected, suggesting a 
transient effect on telomere binding by Hsp90 inhibition. The increase in binding was 
statistically significant for TRF2 and TRF1 at 2 and 4 hours, compared to untreated and eight 
hours, although 2 and 4 hours were not different from each other, nor were 8 hours and untreated 
(p<0.05). Telomere binding was significantly reduced for Hsp90 at 8 hours compared to 
untreated and 4 hours (p<0.05) but not 2 hours, while untreated, 2 and 4 hours were not 
significantly different from each other.  
To further explore the effect of Hsp90 inhibition on TRF2’s ability to bind the telomere, 
we hypothesized that TRF2 colocalization with TRF1 after treatment would be transiently 
disrupted, as was observed with the ChIP data in Figure 16A and B. TRF1 has been shown to be 
an ideal telomere marker, no matter the treatment conditions (Broccoli, et al., 1997; Karlseder, et 
al., 2002). Using immunocytochemistry, the TRF2/TRF1 colocalization significantly decreased 
over time with chronic 0.3µM RAD (p<0.05) (Figure 17 and 18) when untreated is compared to 
all treatment time points, which conflicts with the ChIP data, that shows a significant increase in 
“telomere binding” at two hours. 4, 8, and 16 hours do not significantly differ from each other or 
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Figure 16. Inhibition of Hsp90 affects TRF2 and TRF1 telomere binding. Using chromatin 
immunoprecipitation and a telomeric probe, antibodies for the indicated proteins suggest an 
interaction with telomere sequences after Hsp90 inhibition. A. Chronic treatment with 0.3µM 
RAD up to 8 hours was performed on H1299 cells. IgG serves as a negative control. Input is 1-
2% sheared DNA and serves as the positive control for hybridization. B. Quantitation of 
telomeric binding with treatment compared to untreated ChIP samples. IgG was subtracted out as 
background. Duncan’s new multiple range test indicates a significant difference (p < 0.05) for 
TRF2 telomere binding at 2 hours compared to 8 hours and untreated  (*) and 4 hours compared 
to 8 hours and untreated (*). For TRF1, Duncan’s new multiple range test indicates a significant 
difference (p < 0.05) between 2 hours and 8 hours and 2 hours and untreated (*), 4 hours and 8 
hours and 4 hours and untreated (*). Hsp90 telomere binding was significantly different between 
8 hours and 4 hours and 8 hours and untreated (p<0.05) (*).  
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Figure 17. Inhibition of Hsp90 affects TRF1/TRF2 colocalization. H1299 cells were treated 
for time points indicated with 0.3µM Radicicol. Immunocytochemistry shows a transient 
decrease in TRF2 (Alexa 568) and TRF1 (Alexa 488) interaction with treatment. Nuclear 
punctate staining of both proteins is retained over time although a reduction in overall TRF1 
intensity is observed during treatment.  DAPI serves as a control for nuclear staining.  
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Figure 18. Quantitation of TRF1/TRF2 colocalization. Colocalization analysis using the Leica 
Lite masked cytofluorogram software average of 3 fields shows nuclear colocalization of TRF1 
and TRF2 with chronic 0.3µM RAD treatment that decreases over time. A Duncan’s new 
multiple range test indicates a significant difference (p<0.05) for untreated when compared to all 
time points (*). 2 hours is significantly different from 16 hours and untreated (*).  
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 from 2 hours, while 2 hours is significantly different from 16 hours (p<0.05). The results in 
Figures 16, 17, and 18 suggest that Hsp90 plays some role in TRF1 and/or TRF2’s ability to bind 
to the telomere, where absence of Hsp90 at the telomere results in a transient increase followed 
by a reduction of telomeric protein binding over time.  
To examine the effect Hsp90 inhibition has on the interaction between TRF1/TRF2 and 
Hsp90/Hsp70 using the H1299 cell line, cells were chronically treated with 0.3µM Radicicol for 
2, 4, 8, and 16 hours. We hypothesized that the reduction in telomere binding visualized by ChIP 
after RAD treatment would be reflected in a reduction in Hsp90, TRF2 and TRF1 protein levels 
and in Hsp90/TRF2 and Hsp90/TRF1 interactions. Sonicated whole cell lysates were obtained 
and Western blots were probed for Hsp90, Hsp70, and TRF2. As shown in Figure 19A and B, a 
trend toward decreased Hsp90 and Hsp70 levels was observed at 2 hours up to 8 hours, with an 
increase at 16 hours. TRF2 level fluctuations were minimal, while p23 levels seemed relatively 
unaffected. Quantitation of protein levels by densitometry suggest this trend in fluctuation of 
Hsp90 and Hsp70 levels with chronic RAD treatment was not significant.  Long term chronic 
treatment with 0.3µM RAD up to five days from one independent experiment showed no change 
in Hsp90 or Hsp70 levels (Figure 19C and 19D), suggesting RAD’s effect on proteins is early 
and transient.  
To further determine the effect RAD exerts on Hsp90, H1299 cells were treated with 
0.3µM RAD for 2 hours. Hsp90, normally localized primarily to the cytoplasm (Figure 20, left 
panel), can be seen throughout the cell after treatment, including in the nucleus (as identified by 
the DAPI staining) (Figure 20, right panel). The change in localization of Hsp90 suggests that 
after inhibition, Hsp90 relocalizes to the nucleus to act on nuclear proteins, such as TRF1 and 
TRF2 in response to RAD treatment. 
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Figure 19. Hsp90 inhibition results in variable change in chaperone protein levels but no 
change in TRF2 protein levels in H1299 cells. A. A Western blot of 50µg protein (for Hsp90, 
Hsp70, Actin and p23) or 100µg of protein (for TRF2) from sonicated whole cell extracts was 
performed after treatment with 0.3µM Radicicol for indicated time points. Actin serves as a 
loading control. B. Quantitation of protein level change in part A by densitometry from two 
separate experiments. Cells were first normalized to the loading control and then normalized to 
untreated controls (IDV set to a value of 1). C. Cells were chronically treated for 5 days with 
0.3µM Radicicol. Western blot probed for Hsp90 and Hsp70 is shown (50µg protein loaded). 
Actin serves as a loading control. D. Quantitation of protein levels in part C by densitometry 
from one experiment. Cells were first normalized to the loading control and then normalized to 
day 1 (IDV set to a value of 1). 
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untreated 0.3µM RAD 2 hrs
 
 
Figure 20. Inhibition of Hsp90 disrupts Hsp90 localization in H1299 cells. After chronic 
treatment with 0.3µM Radicicol for two hours, Hsp90 shows a marked change in localization 
from primarily cytoplasmic (left panel, untreated) to cytoplasmic and nuclear (right panel). DAPI 
indicates nuclear staining (bottom panels).  
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Inhibition of Hsp90 affected its localization in the cell as well as TRF1 and TRF2’s 
ability to bind to the telomere. We observed that the interaction between Hsp90/Hsp70 and 
TRF2/TRF1 was also affected by inhibition of Hsp90. Up to 16 hours of chronic treatment with 
0.3µM RAD resulted in a disruption of the interaction between TRF2 and chaperones, as 
evidenced by Co-IP/Western of nuclear extracts. Only the 16 hour Hsp70/TRF2 interaction was 
significantly disrupted when compared to all time points and untreated (p<0.05) (Figure 21A and 
21B) and at 8 hours the TRF2/Hsp90 interaction was significantly disrupted when compared to 
untreated (Figure 21B). To ensure that the timing of the sample collection had no effect on the 
interaction, samples were all collected at the same end point, 16 hours (with treatment for the 
amount of time indicated) (Figure 21A, bottom panel), while in Figure 21A, top panel, samples 
were all treated at the same start time, followed by collection at the time points indicated.  
Results in the two experiments were nearly identical, suggesting that experimental protocol had 
no effect on the disruption of the chaperone/TRF2 interactions. Cytoplasmic extracts Co-IP’d for 
TRF2 and probed for Hsp90 and Hsp70 showed no interaction between Hsp90, Hsp70 and TRF2 
in untreated cells as would be expected because TRF2 is a nuclear protein and Hsp90 localizes to 
the nucleus after treatment (Figure 21C, Figure 20). An interaction between Hsp70 and TRF2 is 
observed after RAD treatment, which peaked at 8 hours, while the Hsp90/TRF2 interaction 
remained almost undetectable even after treatment (Figure 21C). The presence of a modest 
Hsp90/TRF2 interaction at 8 hours (Figure 21C and 21D) suggests that (a very small fraction of) 
TRF2 may be exported to the cytoplasm for proteasome-mediated degradation mediated by 
Hsp90. The strong interaction of Hsp70 and TRF2 in the cytoplasm was unexpected. Given this 
unusual finding, it is possible that the Hsp70/TRF2 interaction is an artifact of the Co-IP 
technique as we find little data to support the cytoplasmic localization of TRF2.  
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Figure 21. Hsp90 inhibition affects interaction levels between chaperones and TRF2 in 
nuclear and cytoplasmic extracts of H1299 cells. A. Cells were treated with 0.3µM Radicicol 
for 2, 4, 8, and 16 hours. Nuclear extracts were then immunoprecipitated with TRF2 antibody 
and Western blots for Hsp90 and Hsp70 were performed. In the top panel, samples were treated 
together and collected at time points indicated. In the bottom panel, treatment time points were 
staggered so that the collection occurred at the 16 hr time point. B. Quantitation through 
densitometry of five separate experiments and Duncan’s new multiple range test shows a 
significant change in the interaction between TRF2 and Hsp90 at 8 hours compared to untreated 
samples (p<0.05) (*) and between Hsp70/TRF2 at 16 hours compared to all other treatments (*). 
Samples were normalized to untreated samples, set to an IDV value of 1. C. Cells were treated 
with 0.3µM Radicicol for 2, 4, 8, and 16 hours. Cytoplasmic extracts were then 
immunoprecipitated with TRF2 antibody and Western blots were probed for Hsp90 and Hsp70. 
D. Quantitation through densitometry of a single cytoplasmic experiment from (C). Samples 
were normalized to untreated samples, set to an IDV value of 1. 
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The interaction between Hsp90, Hsp70 and TRF1 was also disrupted by inhibition of 
Hsp90 in H1299 cells, although the disruption differs from that seen with TRF2/Hsp90. At 8 
hours, there is a significant increase (p<0.05) in the Hsp90/TRF1 interaction compared to 
untreated and to 2, 4, and 16 hour time points as evidenced by Co-IP/Western of nuclear extracts 
(Figure 22A and 22B). The Hsp70/TRF1 interaction at 16 hours is significantly different from 2 
hours and untreated, while 8 hours is significantly different from 2 hours, 4 hours, and untreated 
samples (p<0.05) (Figure 22A and 22B). Compared to TRF2 where we observed a reduction that 
is significant at 8 hours (Figure 21B), we observed a significant increase in the TRF1/Hsp90 
interaction at 8 hours (Figure 22B). The difference in timing between the Hsp90 interactions 
with TRF1 and TRF2 suggests that Hsp90 may be binding to one protein in response to treatment 
to stabilize it and then switching to the other, although this has yet to be determined.  
To confirm results from the Co-IP/Westerns, we examined Hsp90/TRF2 interaction in 
cells using immunocytochemistry. TRF2, as a nuclear telomeric protein, normally displays 
nuclear punctate immunoflourescent staining in cells. We chronically treated cells up to 16 hours 
with 0.3µM RAD and assessed changes in colocalization with Hsp90 and punctate staining of 
TRF2. Using the Leica LCS Lite image analysis software, pixel distribution was analyzed for 
colocalization of two fluorophores at once. The masked cytofluorogram program quantifies and 
analyses the percentage of colocalization between Alexa 488 (Hsp90) and Alexa 568 (TRF2) for 
nuclear colocalization of pixels from three separate fields. No differences in TRF2 punctate 
staining were observed over time, and Hsp90 and TRF2 colocalized to varying degrees at all 
time points (Figure 23 and 24). Quantitation of colocalization using the Leica Lite masked 
cytofluorogram software revealed that nuclear colocalization of Hsp90 and TRF2 significantly 
increased at 4 hours (p<0.05) above the untreated and all other time points (Figure 24). 16 hour  
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Figure 22. Hsp90 inhibition affects interaction levels between chaperones and TRF1 in 
H1299 cells. A. Cells were treated with 0.3µM Radicicol for 2, 4, 8, and 16 hours. Nuclear 
extracts were then immunoprecipitated with TRF1 antibody and Western blots for Hsp90 and 
Hsp70 were performed. B. Quantitation through densitometry of three separate experiments 
shows a significant difference (Duncan’s new multiple range test, p<0.05) in the interaction 
between TRF1 and Hsp90 with 8 hours compared to all treatment times (*). The Hsp70/TRF1 
indicates a significant difference between 16 hours, 2 hours and untreated (*) and between 8 
hours and 2 hours (*), 4 hours and untreated (*) (p<0.05). Samples were normalized to untreated 
samples, which was set to an IDV value of 1.  
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Figure 23. Inhibition of Hsp90 affects the colocalization of Hsp90 and TRF2 in H1299 cells. 
H1299 cells were chronically treated for time points indicated with 0.3µM Radicicol. 
Immunocytochemistry shows no change in TRF2 (Alexa 568) in the nucleus with treatment as 
punctate staining is retained over time.  Hsp90 (Alexa 488) primarily stains the cytoplasm, with a 
change in localization beginning at 2 hours of treatment up to 16 hours, where it can be seen in 
the nucleus colocalizing with TRF2. DAPI serves as a control for nuclear staining.  
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Figure 24. Quantitation of TRF2/Hsp90 colocalization. Colocalization analysis using the 
Leica Lite masked cytofluorogram software average of 3 fields shows a transient change in 
nuclear colocalization of Hsp90 and TRF2 with RAD treatment over time. Duncan’s new 
multiple range test suggests a significant change at 4 hours (*) and 16 hours (*) compared to all 
time points and untreated (p<0.05). 
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was also significantly different from all time points and untreated (p<0.05) (Figure 24). The 
transient change in the nuclear colocalization between Hsp90 and TRF2 almost perfectly 
parallels the transient changes observed in Co-IP/Western results (Figure 21A). No detectable 
changes in TRF2 localization suggest that Hsp90 inhibition has no deleterious effect on the 
TRF2 protein itself (i.e. degradation) (Figure 23), as protein levels are relatively unaffected with 
treatment (Figure 19A). In addition, RAD treatment does not appear to induce exportation to the 
cytoplasm for proteasome-mediated degradation. Colocalization signals seen in the cytoplasm 
are likely due to background or small amounts of TRF2 localizing to the cytoplasm for 
degradation due to normal protein turnover (Figure 23), as we previously showed with a lack of 
Hsp90 and TRF2 interaction in the cytoplasm (Figure 21C). 
TRF1, as a telomeric protein, also normally displays nuclear punctate immunoflourescent 
staining in cells. We chronically treated cells up to 16 hours with 0.3µM RAD and assessed 
changes in colocalization with Hsp90 and punctate staining of TRF1. TRF1 localization 
remained nuclear and mostly punctate with RAD treatment (Figure 25), although TRF1 appeared 
more diffuse at 2 and 4 hours. Quantitation by the Leica Lite software showed that nuclear 
colocalization of Hsp90 and TRF1 significantly increased at 8 and 16 hours compared to 
untreated and 2 and 4 hours (p<0.05) (Figure 26) similar to results from the Co-IP/Westerns, 
which showed a significant increase in Hsp90/TRF1 nuclear interaction at 8 hours and almost no 
interaction at 2 hours (Figure 22A). Again, this may be indicative of an Hsp90 protein interaction 
switching from TRF2 to TRF1 due to RAD treatment. Untreated, 2 hours and 4 hours were not 
significantly different from each other nor were 8 and 16 hours.  
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Figure 25. Inhibition of Hsp90 transiently affects the colocalization of Hsp90 and TRF1 in 
H1299 cells. H1299 cells were treated for time points indicated with 0.3µM Radicicol. 
Immunocytochemistry shows nuclear TRF1 (Alexa 488), while Hsp90 (Alexa 568) stains the 
cytoplasm and nucleus. A transient change in Hsp90/TRF1 colocalization was observed. DAPI 
serves as a control for nuclear staining. 
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Figure 26. Quantitation of TRF1/Hsp90 colocalization. Analysis by Leica Lite masked 
cytofluorogram colocalization software of an average of 3 fields showed nuclear co-localization 
of TRF1 and Hsp90 increased significantly at 8 (*) and 16 (*) hours compared to untreated, 2 
and 4 hours (Duncan’s new multiple range test, p<0.05). 
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TRF2, TRF1 and POT1 are the only Shelterin proteins that bind directly to telomeric 
DNA, but a weak signal from TIN2 and TPP1 may be seen if they are closely interacting with 
TRF2 or TRF1, as evidenced by ChIP data (Figure 10A). One function of Hsp90 is to aid in 
protein-protein interactions of its client proteins. Because we observed that Hsp90 also interacts 
with the telomeric proteins TIN2 and TPP1, and Hsp90 inhibition effects TRF1/TRF2 interaction 
(Figure 12D, 17 and 18), we hypothesized that the interaction of Hsp90 with TRF2 may function 
in its interactions with other telomere proteins such as TIN2 and TPP1, possibly enhancing or 
preventing direct interactions. To explore this, we inhibited Hsp90 using chronic RAD treatment 
at 0.3µM up to 6 hours. Immunocytochemistry revealed a significant increase in TRF2/TIN2 
colocalization with chronic treatment of 0.3µM RAD at 2 hours (p<0.05) (Figure 27 and Figure 
28). A significant increase in TRF2/TPP1 colocalization with treatment was observed at all times 
points (p<0.05) compared to untreated, as well as at 1 hours compared to 2 hours treatment 
(p<0.05) (Figure 29 and Figure 30). Together, these data suggest that inhibition of Hsp90 effects 
TIN2 and particularly TPP1’s ability to interact with TRF2 compared to untreated samples. This 
is especially interesting for the TRF2/TPP1 interaction, as these proteins do not normally interact 
directly but associate through the TRF2/TIN2 interaction. ChIP data showed an increase in TIN2 
and TPP1’s ability to bind to the telomere after 2 hours of chronic RAD treatment (data not 
shown), suggesting an increase in telomere binding of TIN2 and TPP1 (or association with 
telomere binding proteins such as TRF1 and TRF2) as was reflected in the 
immunocytochemistry results shown in Figure 27-30. The apparent increase in telomeric access 
is reflected in the increase in TRF2 colocalization with both TIN2 and TPP1, suggesting that 
Hsp90 has a direct effect on TRF2’s ability to bind other Shelterin proteins. Therefore, we have 
determined that Hsp90 interacts with TRF1, TRF2, TIN2 and TPP1 and that inhibition of Hsp90  
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Figure 27. Inhibition of Hsp90 transiently affects the colocalization of TRF2 and TIN2 in 
cells. H1299 cells were chronically treated for time points indicated with 0.3µM Radicicol. 
Immunocytochemistry shows an increase in TRF2 (Alexa 488) colocalization with the telomere 
associated protein TIN2 (Alexa 568) at 2 hrs. DAPI serves as a control for nuclear staining. 
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Figure 28. Quantitation of TRF2/TIN2 colocalization. Analysis by Leica Lite masked 
cytofluorogram colocalization software of 3 fields showed nuclear co-localization of TRF2 and 
TIN2 increased significantly at 2 hours compared to all other time points (Duncan’s new 
multiple range test (*) (p<0.05). 
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Figure 29. Inhibition of Hsp90 has an effect on the colocalization of TRF2 and TPP1 in 
cells. H1299 cells were treated for time points indicated with 0.3µM Radicicol. 
Immunocytochemistry shows an increase in TRF2 (Alexa 488) colocalization with the telomere 
associated protein TPP1 (Alexa 568) at each time point. DAPI serves as a control for nuclear 
staining. 
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Figure 30. Quantitation of TRF2/TPP1 colocalization. Analysis of nuclear colocalization by 
the Leica Lite masked cytofluorogram shows a transient change in colocalization of TRF2 and 
TPP1 over time, which is significantly increased at all time points compared to untreated 
controls (Duncan’s new multiple range test (*) (p<0.05). 1 hour is significantly increased 
compared to 2 hours (*) (p<0.05). 
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affects TRF2’s ability to colocalize with TRF1, TIN2 and TPP1. Inhibition of Hsp90 also affects 
Hsp90’s ability to interact with TRF1 and TRF2, all suggesting a role for Hsp90 in protein-
protein interactions at the telomere. 
 
Ubiquitination of TRF2 
Inhibition of Hsp90 is known to target client proteins for proteasome-mediated 
degradation (Shulte, et al., 1997). We hypothesized that through protein-protein interactions and 
telomere binding, Hsp90 may be stabilizing TRF2 and/or TRF1 at the telomere in cancer cells; 
therefore, inhibition of Hsp90 could result in degradation of TRF2 and/or TRF1. An initial 
experiment (Figure 21C) suggests that TRF2 is not interacting with Hsp90 in the cytoplasm, yet 
it remains possible that TRF2 is being degraded quickly and we are unable to account for it in the 
Co-IP/Westerns. To determine if TRF2 was interacting with chaperones in the cytoplasm, thus 
suggesting proteasome-mediated degradation, cells were chronically treated with 0.3µM RAD 
and 10µM of the proteasome inhibitor MG132. If Hsp90 targets TRF2 for proteasome-mediated 
degradation, MG132 could prevent degradation of TRF2 and cause localization to the cytoplasm, 
as it would still be exported from the nucleus but not degraded. Nuclear and cytoplasmic extracts 
were Co-IP’d after treatment for TRF2 followed by Western analysis for Hsp90 and Hsp70. 
Nuclear extracts showed disruption in interactions between Hsp90 and TRF2 at 2 and 4 hours 
(Figure 31, left panel), which differed slightly from that seen in Figure 21A. It is important to 
note that Hsp90 and TRF2 still interact over time and addition of MG132 does not seem to have 
an effect on the Hsp90/TRF2 association, suggesting that Hsp90 inhibition does not cause TRF2 
degradation. In cytoplasmic extracts, Hsp90/TRF2 interactions are undetectable (Figure 31, right  
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Figure 31. Hsp90 inhibition has little effect on chaperone and TRF2 interaction and 
localization. H1299 cells were treated with 0.3µM Radicicol with the proteasome inhibitor 
MG132 (10µM) at the times indicated. Nuclear and cytoplasmic extracts were 
immunoprecipitated for TRF2 and Western blots were probed for Hsp90 and Hsp70. IgG serves 
as a negative control. Hsp90 and TRF2 only interact in the nucleus, while Hsp70 and TRF2 
interact in both the nucleus and the cytoplasm.  
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panel), as observed previously (Figure 21C). Consistent with Figure 21C, the Hsp70/TRF2 
interaction was observed in nuclear and cytoplasmic extracts after treatment, suggesting again 
the potential for artifactual IP results as there is no evidence for TRF2 exportation to the 
cytoplasm (Figure 21C and Figure 31, right panel).  
To verify the results and ensure that TRF2 is not interacting with Hsp90 as a means to be 
targeted for degradation, further examination of TRF2 ubiquitination was performed. H1299 
cells were chronically treated with 0.3µM RAD with or without 10µM MG132 up to 24 hours. 
Co-IPs were performed for TRF2 and Westerns were probed for Ubiquitin. Ubiquitination of 
TRF2 displays a characteristic laddering signal above TRF2. When nuclear and cytoplasmic 
extracts were compared, more ubiquitination was observed in the cytoplasm in Figure 32 (lower 
panel), but this low intensity pattern likely was the result of normal TRF2 protein turnover rather 
than a drug-induced degradation. In addition, low intensity bands in the nuclear extracts were 
likely also due to normal protein turnover (Figure 32, upper panel). Collectively, our data 
suggests that Hsp90 inhibition by Radicicol treatment does not cause TRF2 degradation. 
Our results show that when H1299 cells were chronically treated with 0.3µM RAD and 
10µM MG132 for 2 hours TRF1 appeared to be ubiquitinated in response to Hsp90 inhibition 
(Figure 33), suggesting Hsp90 inhibition results in targeting TRF1 for degradation. In an effort to 
determine if TRF1 is ubiquitinated, nuclear extracts were collected and immunoprecipitated 
against TRF2, TRF1, IgG, and Ubiquitin in treated and untreated samples and Western blots 
were probed for Ubiquitin. Consistent with previous results (Figure 21C and Figure 32), the 
levels of TRF2 ubiquitination did not differ from basal levels of degradation and can be 
explained by normal protein turnover.  
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Figure 32.  Inhibition of Hsp90 does not target TRF2 for ubiquitination.  Cells were treated 
with 0.3µM RAD with or without 10µM MG132. Nuclear and cytoplasmic fractions were 
collected and immunoprecipitated for TRF2 and Westerns were probed for Ubiquitin. Very low 
intensity bands above TRF2 (65-69 kDa) indicate levels of ubiquitination as a result of normal 
protein turnover and likely not proteasome-mediated degradation as a result of Hsp90 inhibition.  
77 
 
 
IP:
170 kDa
130 kDa
100 kDa
70 kDa
55 kDa
untreated treated (2 hrs)
 
Figure 33. Inhibition of Hsp90 results in ubiquitination of TRF1. H1299 cells were treated 
for 2 hours with Radicicol and 10µM MG132 compared to untreated cells. Nuclear extracts were 
immunoprecipitated for TRF2, TRF1, IgG (negative control), and Ubiquitin (positive control) 
and Western blots were probed for Ubiquitin.  
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To visually confirm these results through immunocytochemistry and determine if Hsp90 
targeted TRF1 for degradation, we chronically treated H1299 cells with both 0.3µM RAD and  
10µM MG132. MG132 is toxic to cells at 6 hours, so we assayed for changes in colocalization 
out to 4 hours. When analyzed by the Leica Lite masked cytofluorogram program, colocalization 
between Hsp90 and TRF1 significantly increased in the nucleus at 4 hours compared to untreated 
(p<0.05) with no evidence of TRF1 being exported to the cytoplasm for degradation (Figure 34). 
Therefore, the interaction between Hsp90 and TRF1 after Hsp90 inhibition does not seem to 
result in cytoplasmic proteasome-mediated degradation, but may be being degraded in the 
nucleus of tumor cells after Hsp90 inhibition.  
Together, these data suggest that the Hsp90/TRF2 interaction is affected only transiently 
by Hsp90 inhibition with RAD. The inhibition of Hsp90 had no significant effect on TRF2 
localization in the cell nor did it target TRF2 for degradation but effects telomere binding and 
protein-protein interactions transiently. Hsp90 may, however, play a role in TRF2’s ability to 
associate with the telomere long-term, which could have implications for chronic Hsp90 
inhibition as a means to block TRF2’s telomere binding function. TRF1/Hsp90 interactions are 
also transiently affected by Hsp90 inhibition, and this Hsp90/TRF1 interaction may have 
implications in targeting TRF1 for proteasome-mediated degradation in the nucleus rather than 
the cytoplasm.  
 
Radicicol does not induce DNA Damage 
It is possible that inhibition of Hsp90 is inducing a DNA damage response at the 
telomere, as TRF2 is known to localize to sites of DNA damage, both telomeric and throughout 
the genome (Tanaka, et al., 2005; Bradshaw, et al., 2005; Karlseder, et al., 2004; Demuth, et al., 
2008). We hypothesized that TRF2 was binding to Hsp90 to not only affect telomere binding or  
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Figure 34. Inhibition of Hsp90 and proteasome-mediated degradation affects colocalization 
of chaperones and TRF1 in cells. H1299 cells were treated with 0.3µM Radicicol and 10µM 
MG132. Immunocytochemistry and analysis by Leica Lite masked cytofluorogram 
colocalization software of 3 fields showed significant increase in colocalization of Hsp90 (Alexa 
568) and TRF1 (Alexa 488) in the nucleus at 4 hours compared to untreated (*) (Duncan’s new 
multiple range test, p<0.05). TRF1 stains the nucleus throughout treatment, indicating a lack of 
localization to the cytoplasm. DAPI serves as a positive control for nuclear staining. 
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protein-protein interactions but also in response to DNA damage or critically short telomeres. To 
explore this, we wanted to determine if there was an increase in telomere end-end fusions as an  
indicator of DNA damage. After up to 16 hours of chronic treatment with 0.3µM RAD, no end-
end fusions were detectable using the Telomere Restriction Fragment length assay (TRF) under 
denaturing conditions (Figure 35B), an assay that has been used previously to detect end-end 
fusions (Karlseder, et al., 2002). When end-end fusions occur, high molecular weight bands are 
observed above the normal telomeric smear (Figure 35A, 8 hour and 16 hour). No distinct bands 
were observed in the RAD treated H1299 samples, suggesting Hsp90 inhibition did not cause 
telomere dysfunction at levels detectable by the crude TRF assay. 
Cytogenetic chromosomal aberrations are also an indicator of DNA damage and genomic 
instability. To determine if Hsp90 inhibition induced genomic instability or affected telomere 
structure over a longer treatment period, we examined the telomeres of metaphase chromosomes. 
The chromosome assessments included evaluations of the telomeric signals (location and 
number) and the presence of structural aberrations, with particular attention given to changes 
involving telomeric regions (such as end-to-end associations or terminal deletions). Although a 
trend toward a higher number of telomeres lacking signal was observed for the cells after 
exposure to RAD (when compared to controls), there appears to be no significant differences in 
telomere-related chromosomal changes after Hsp90 inhibition (p>0.05) (Figure 36A and 36D 
and Table 2).  Interestingly, the cells from the 3-day exposure did have a significantly increased 
frequency of chromosomes presenting with a “double” telomeric signal (p<0.05). This unusual 
finding (Figure 36C) was characterized by the presence of “doublet” signals in multiple (at least 
two) areas of hybridization on the telomeres of the affected chromatids.  However, by day 5 of 
treatment, the “doublet” telomeric regions were no longer observed, with no other significant  
81 
 
23 kb
9.4 kb
6.5 kb
4.3 kb
11 kb
10 kb
9 kb
8 kb
7 kb
6 kb
5 kb
4 kb
A B
23 kb
9.4 kb
6.5 kb
4.3 kb
9 kb
7 kb
6 kb
5 kb
4 kb
8 kb
schematic
11 kb
10 kb
experimental
 
 
Figure 35. Hsp90 inhibition does not induce end-end fusions. A. A schematic representation 
of a Telomere Restriction Fragment length assay (TRF) in which drug treatment induces a DNA 
damage response, resulting in end-end fusions of chromosomes. When genomic DNA is 
enzymatically digested and loaded, end-end fusions cause a high molecular weight band above 
the telomeric smear. B. A TRF assay was performed after 0.3µM Radicicol treatment for times 
indicated to identify telomeric end-end fusions, an indicator of DNA damage, in H1299 cells. 
10µg of genomic DNA was enzymatically digested and loaded.  
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Figure 36. Representative metaphase spreads from H1299 cultures following treatment 
with Radicicol.  A. The baseline (untreated) metaphase spreads from this chromosomally 
abnormal cell line had a near-tetraploid complement. Most of the telomeres had two signals (one 
for each chromatid). However, 6% of the chromosomes scored had a single telomeric signal (as 
illustrated by the chromosome highlighted by the red arrow). B. The telomeric signals and 
chromosomal findings that were observed following 1 day of treatment with Radicicol were not 
significantly different from those seen in the baseline culture. C. Following 3 days of treatment, 
chromosomes were observed that had one (red arrow) or no (yellow arrow) telomeric signals. 
Interestingly, several of the chromosomes had an apparent doubling of their telomeric signals 
(white arrow indicates area that is enlarged in the inset picture. The inset shows 3 chromosomes 
having a multi-signal telomeric appearance). D. After 5 days of treatment, this atypical, multi-
signal telomeric appearance was no longer observed, with no other significant change in the 
telomeres being detected when compared to chromosomes from the baseline cultures. 
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Table 2. Cytogenetic findings after Hsp90 Inhibition 
Metaphase 
spreads from 
treatment
Mean  
Xsome arms 
without 
telomere 
signal
Mean 
Xsomes with 
1 chromatid 
telomere
Mean 
Xsomes
with very 
small signal
Mean 
aberrations
Mean 
“double” 
signals at 
telomeres
Control (n=5) 1.6 (0-3)* 6.0 (2-16) 6.0 (4-9) 0.4 (0-2) 0.4 (0-1)
Day 1 (n=7) 1.3 (0-3) 5.1 (0-9) 7.0 (1-15) 0.4 (0-1) 1.3 (0-4)
Day 3 (n=7) 5.7 (1-17) 7.9 (0-18) 5.7 (1-12) 2.1 (1-6) 5.6 (2-9)¶
Day 5 (n=7) 1.6 (0-4) 3.9 (0-8) 4.0 (1-7) 0.1 (0-1) 0.6 (0-2)
*Mean (range/cell)
¶ Significantly increased in cells from day 3 treatment
While there is a trend toward a higher number of chromosomes lacking a telomeric signal in the day 3 treatment 
this value is not significantly different [Chi-square, 3df].
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differences in telomeric attributes being detected when compared to the chromosomes from 
control cultures. This doublet finding has been described in human cells to be associated with an 
induction of TIFs, growth arrest and cellular senescence (Philippe, et al., 1999; van Overbeek 
and de Lange, 2006; Mitchell, et al. 2009), particularly when TRF2 is disrupted. The doublet 
findings here suggest that Hsp90 inhibition is, in fact, having some sort of deleterious effect on 
TRF2, resulting in an inability to properly protect telomeres.  
 
Proposed model of TRF1 and TRF2 interaction with Hsp90 
In this study, we show both in vitro and in vivo that TRF2 and TRF1 interact with Hsp90 
and Hsp70. Additionally, Hsp90 and Hsp70 were found to interact with the telomere associated 
proteins, TPP1 and TIN2. The telomere is normally coated by TRF1 while TRF2 facilitates the 
formation of the t-loop by promoting invasion of the 3’ overhang into the duplex DNA. Our 
results suggest that Hsp90 normally directly interacts with both TRF1 and TRF2 through a cycle 
of binding and unbinding to the telomere at the t-loop (Figure 37, right). Clearly, we need to 
investigate the role of Hsp90 in t-loop formation, but these experiments are not only costly but 
technically challenging, to the point where only a single lab (Griffith, et al., 1999) can 
adequately perform these assays. That said, we have established a collaboration and are hopeful 
that these results will be obtained soon. 
When Hsp90 is pharmacologically inhibited by Radicicol, Hsp90 comes off of the 
telomere inducing initial tight binding at the telomere of TRF1 and TRF2. The reason for this 
initial increase in telomere binding by TRF1/TRF2 after blocking Hsp90 remains unclear, but the 
function of most, if not all, Hsp90 client proteins does not require constant “contact” with the 
Hsp90 protein. The vast majority of Hsp90 target proteins only associate with chaperones in a  
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Figure 37. Model of proposed interactions of chaperone proteins at the telomere. TRF2 and 
TRF1 interacts with Hsp90. We propose that these two telomeric proteins normally bind to 
Hsp90, and Hsp90 goes through a cycle of binding and unbinding at the t-loop (right). If Hsp90 
is inhibited, there is an initial tight binding to the telomere by TRF1 and TRF2. With chronic 
RAD treatment, there is increased protein turnover and destabilization of the t-loop, leading to 
long term telomere deprotection and eventual telomere shortening. 
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transient fashion, so the initial Hsp90 inhibition followed by an increase in TRF1/TRF2 telomere 
binding is consistent with previously accumulated data (Prodromou, et al., 2000; reviewed in 
Hahn, 2009). With chronic long-term RAD treatment, there appears to be an increase in TRF1/2 
protein turnover, which may be the result of TRF1 degradation (seen in Figure 33), ultimately 
leading to destabilization of the t-loop and long-term telomere deprotection and shortening 
(Figure 37, left).  
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Chapter 6 
Discussion 
 
The Chaperone/Telomere Interaction 
 When normal somatic cells divide, telomeres gradually erode until they reach a critical 
length. As the telomere shortens, there is less substrate for telomere binding proteins, including 
TRF1 and TRF2, to maintain the t-loop structure and mask the telomere from the DNA damage 
response machinery. This destabilization can result in the cytogenetic abnormalities of telomere 
dysfunction: end-end associations/fusions, anaphase bridges, radials, dicentric chromosomes, and 
overall genomic instability, which is a major factor in tumorigenesis. TRF2 protects the 
telomeres from end-end fusions and the resulting genomic instability and is required for proper 
telomere structure (van Steensel, et al., 1998), while TRF1 coats the telomeric DNA and has 
been shown to prevent telomerase access to the telomere (Smorgorzewska, et al., 2000). 
Therefore, defining the mechanisms of TRF1 and TRF2 regulation is important for both 
understanding the telomere and in the development of new therapeutic approaches for targeting 
telomeres to induce dysfunction in human tumors. One way to accomplish this may be through 
inhibition of the chaperone proteins, particularly Hsp90, which has been shown to be important 
in the treatment of many types of cancer. Clinical trials are underway employing drugs targeting 
Hsp90 in cancer cells (Banjeri, et al., 2005; Goetz, et al., 2005; Grem, et al., 2005), and given 
the results here, these Hsp90 compounds have an effect on telomeric proteins.  
Our previous studies have demonstrated that Hsp90 and p23 stably associate with 
telomerase, so it has been inferred that telomerase-bound chaperones will be associated with the 
telomere (Holt, et al., 1999). In the present study, we have not only shown a specific interaction 
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of chaperones with telomeres, we have also identified a novel interaction between the chaperone 
proteins Hsp90 and Hsp70 and the telomere proteins TRF2, TRF1, TIN2 and TPP1. We 
speculate that this interaction may have an integral role in protection of the telomere and/or 
telomeric structure and the ability of telomere proteins to associate with the telomere and each 
other in cancer cells.  
 
TRF2 and Hsp90 
In defining the function of the chaperone/telomere association, we focused on the 
TRF2/Hsp90 interaction. Because there are known inhibitors of Hsp90 that are presently in 
Phase II clinical trials, pursuing the effect of these drugs, particularly Radicicol, provides clinical 
relevance to our results. As TRF2 is a major player in the protection of the telomere, this 
interaction may play a specific role in telomere stability and may be an attractive therapeutic 
target.   
Pharmacologic inhibition of Hsp90 over 16 hours had no effect on TRF2 protein levels 
nor did it effect TRF2 localization in the cell. Hsp90 protein levels decreased with inhibition, and 
Hsp90 localization changed from almost exclusively cytoplasmic to both nuclear and 
cytoplasmic. Hsp90 levels began to return to untreated levels at 16 hours and remained stable 
with long term chronic treatment, up to 5 days, possibly due to an increase in association with 
nuclear proteins responding to the stress of chronic drug treatment. Interestingly, the interaction 
between Hsp90 and TRF2 was transiently disrupted, although TRF2 localization remained 
virtually unaffected. 
As Hsp90 acts to stabilize misfolded or stressed proteins, it would be expected that it 
would bind to those proteins in both the cytoplasm and the nucleus and remain bound until 
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targeted for degradation. We initially hypothesized that Hsp90 was interacting with TRF2 as a 
means to target it for ubiquitination and degradation. In previous studies of the effects of 
Radicicol and Geldanamycin, Hsp90 client proteins are most often targeted for proteasome-
mediated degradation in the cytoplasm after treatment (reviewed in Messaoudi, et al., 2008).  
However, when treated with Radicicol, TRF2 remained stably localized in the nucleus and no 
increase in association with Ubiquitin was observed. To ensure that TRF2 was not being 
degraded prior to sample collection, treatment with the proteasome inhibitor MG132 verified that 
TRF2 remained in the nucleus after treatment and was not being exported to the cytoplasm as a 
means for degradation, suggesting the functional association of Hsp90 and TRF2 is therefore not 
based upon Hsp90 targeting TRF2 for degradation. Any ubiquitination of TRF2 observed 
appears likely the result of normal protein turnover, not due to the Hsp90/TRF2 interaction being 
inhibited through Radicicol treatment that occurs with other Hsp90 client proteins such as Erb-
B2 and mutant p53 (reviewed in Messaoudi, et al., 2008).  
Although pharmacologic inhibition of Hsp90 did not affect TRF2 protein levels or 
localization, it did seem to effect the interaction between Hsp90 and TRF2 and the association of 
TRF2 at the telomere. When treated chronically over 16 hours, the interaction between TRF2 and 
Hsp90 decreased significantly at 8 hours and returned to low levels at 16 hours. The interaction 
remained highly nuclear throughout treatment with only background association detectable in the 
cytoplasm.  When we assessed TRF2’s ability to bind to the telomere (through ChIP and 
colocalization with TRF1, a second telomere binding protein as a marker of telomere 
colocalization), we observed a significant increase in TRF2’s association with telomeric 
sequence at 2 hours and 4 hours of Radicicol treatment when compared to controls, even though 
the Hsp90/TRF2 interaction was blocked. At 8 hours, TRF2 binding was diminished to levels 
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similar to untreated controls. Immunocytochemistry (ICC) showed a significant decrease in 
TRF2/TRF1 colocalization at 8 hours of RAD treatment, which may reflect an effect of Hsp90 
inhibition on TRF1 rather than TRF1/TRF2 colocalization. ImmunoFISH experiments would be 
ideal to verify if Hsp90 inhibition is indeed affecting TRF2’s ability to bind the telomere. It 
appears that inhibition of Hsp90 initially caused elevated binding of TRF2 to the telomere, which 
decreased with continued inhibition of Hsp90.  
These results suggest two possible roles for the Hsp90/TRF2 interaction: (1) Hsp90 
interacts with TRF2 to facilitate TRF2’s binding to the telomere, acting as a conformational 
bridge for proper telomere binding, possibly associating with TRF2 near its DNA binding 
domain. When inhibited, Hsp90 is removed from the complex, leaving a properly folded TRF2 
that is capable of strongly binding to telomere, resulting in an increased TRF2 telomere signal. 
However, at later time points, TRF2 appeared to be unable to stably associate with the telomere, 
suggesting that TRF2 needs Hsp90 to bind to telomeres long-term. A determination of where 
Hsp90 binds to TRF2 may still provide clues as to the functional role between Hsp90 and TRF2. 
If Hsp90 binds at or near the DNA binding domain of TRF2, it is possible that Hsp90 is assisting 
but is not absolutely required for TRF2’s binding to telomeric sequence, which may have 
implications in TRF2’s ability to bind elsewhere and its function in the DNA damage response.  
The Hsp90/TRF2 interaction may play another possible role: (2) Hsp90 may stabilize 
TRF2 at the telomere, acting solely on TRF2 to maintain telomere structure rather than bridging 
the telomere and TRF2. In this scenario, Hsp90 may have an effect on protein turnover, and 
when Hsp90 is inhibited, TRF2’s half-life at the telomere decreases in the long term. Although 
we did not observe an increase in TRF2 ubiquitination, it may be that the rate of turnover is 
increased independent of any sort of post-translational modification.  
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TRF2 is intricately involved in the DNA damage response, both telomerically and 
globally (Tanaka, et al., 2005; Bradshaw, et al., 2005; Karlseder, et al., 2004; Demuth, et al., 
2008). It is the only Shelterin protein to bind to numerous DNA damage proteins found at the 
telomere, including the Mre11 complex, and so far, is the only Shelterin protein implicated in 
sensing DNA damage elsewhere (Karlseder, et al., 1999; Bradshaw, et al., 2005). However, 
Radicicol treatment did not induce a DNA damage response, consistent with what has been 
observed previously (Compton, et al., 2006). We looked for an induction of end-end fusions with 
treatment, which are indicative of a DNA damage response (van Steensel, et al., 1998), but a 
denaturing TRF assay revealed no induction of telomere fusions over the 16 hour treatment time.  
Cytogenetic examination of metaphase spreads over 5 days of chronic treatment with 
Radicicol also revealed no significant increase in loss of telomere signals or structural 
aberrations that would suggest increased DNA damage relevant to TRF2 and/or Hsp90. 
However, at day 3 of treatment there was an increase in a “doublet” telomeric signal. The 
presence of telomeric doublets suggests a Radicicol-induced effect on TRF2, similar to that seen 
previously (Philippe, et al., 1999; van Overbeek, et al., 2006; Mitchell, et al. 2009), where an 
absence of structural chromosomal aberrations but an induction of TIFs was also observed. One 
could speculate that this atypical, doubling of the telomeric area resulted from a change in the 
telomeric chromatin (possible break between regions or duplication of the region) as a result of 
disrupting either the TRF2/Hsp90 or TRF1/Hsp90 interaction. The Hsp90/TRF2 interaction may 
occur so that TRF2 is able to bind to the telomere “loosely” to allow for t-loop formation and 
telomere chromatin unwinding. When the normal Hsp90 interaction is inhibited, the lack of 
association potentially triggers an incomplete DNA damage response involving only TRF2 and 
promotes tight telomere binding of TRF2 to aid in its function of telomere capping and 
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prevention of loss of the t-loop early (2-4 hours). Long term inhibition of Hsp90 (3 days) results 
in a change in telomeric chromatin that alters TRF1/TRF2/telomere binding, thus altering the 
chromatin structure itself. Examination of the t-loop and TRF2’s ability to bind and induce 
strand invasion before and after Hsp90 inhibition may provide conclusions to this hypothesis 
(Stansel, et al., 2001). Even though these results are interesting considering TRF2 has been 
implicated in chromatin remodeling (Amiard, et al., 2007), further examination of the 
TRF2/Hsp90 interaction and its effects on telomeric chromatin and t-loop structure is underway 
with our collaboration with Dr. Sarah Compton at UNC Chapel Hill. 
Although the effects seen in this study were conducted mainly in the H1299 lung 
carcinoma cells, the interaction between Hsp90 and TRF2 also was found in MCF7 breast cancer 
cells, M12 prostate cancer cells, and BJ fibroblast cells (a normal cell culture). Therefore, it is 
likely that the effects observed here occur universally in normal and cancer cell lines. It appears 
that the Hsp90/TRF2 complex is a normally occurring interaction, not influenced by 
dysfunctional or critically short telomeres found in cancer cells. If Hsp90 does, in fact, interact 
with TRF2 as a means to facilitate TRF2 telomere binding, understanding this relationship is 
imperative to understanding how Hsp90 and TRF2 function in the cell. As Hsp90 inhibitors like 
17-AAG have entered into clinic trials for use as adjuvant treatment for breast cancer and 
prostate cancer, it is important to determine how this inhibition effects TRF2’s role in telomere 
structure and function, as disruption of this interaction could effect a vital telomere protective 
factor. A better understanding of both TRF2 and Hsp90 and their roles in nuclear events is 
necessary, as both have extremely important functions in the cell.  
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TRF2 and Hsp70 
 Hsp70 and TRF2 were also found to interact in H1299, MCF7, and BJ cells. RAD 
treatment resulted in a decrease in Hsp70 protein levels earlier than Hsp90, with a return to 
higher levels than Hsp90 at 16 hours. A significant decrease in Hsp70 binding to telomere 
sequence occurred after Hsp90 inhibition when compared to Hsp90. This was all expected after 
Hsp90 inhibition, as Hsp70 complexes with Hsp90 (Wegele, et al., 2004). RAD treatment would 
be expected to result in a similar, if not more dramatic inhibition of Hsp70 because it is likely 
indirectly associating with the telomere, and hence telomere binding proteins, through Hsp90.  
 When treated with Radicicol (with or without MG132), there was no detectable 
cytoplasmic interaction between Hsp90 and TRF2; however the cytoplasmic interaction between 
Hsp70 and TRF2 was significantly increased, particularly at 8 hours. From this, it could be 
hypothesized that TRF2 is binding to Hsp70 to be exported to the cytoplasm for ubiquitination. 
However, there was no increase in TRF2 ubiquitination or cytoplasmic localization after 
Radicicol treatment, suggesting that the interaction observed between Hsp70 and TRF2, 
especially in cytoplasmic extracts, was merely an artifact of Co-IP analysis. It is likely that 
Hsp70 is immunoprecipitating with TRF2 through its association with Hsp90, not through a 
direct association between Hsp70 and TRF2.  
 
TIN2, TPP1 and Hsp90 
 Early inhibition of Hsp90 resulted in a significant increase in TIN2 and TPP1 binding to 
telomeric sequence, similar to that found for TRF2 and TRF1. TIN2 interacts with both TRF1 
and TRF2, forming a bridge between the two proteins, while TPP1 binds to TIN2. Although 
neither TIN2 nor TPP1 interact directly with telomeric DNA, as TRF1 and TRF2 do, the 
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increased association of protein and telomeric sequence suggests that Hsp90 may play a role in 
TIN2 and TPP1 regulation similar to its role with TRF2: facilitating association between the 
telomere and binding proteins. Radicicol treatment had a transient effect on TRF2/TIN2 
interaction implying that Hsp90 may contribute to the protein-protein interactions of the 
Shelterin complex. The TRF2/TPP1 interaction appeared to be enhanced significantly after 
Hsp90 inhibition, which is interesting because these proteins do not directly interact, suggesting 
a role for Hsp90 in mediating telomere protein-protein interactions.  
 TIN2 and TPP1’s novel association with Hsp90 and Hsp70 shows that Hsp90 may be 
interacting with all Shelterin proteins, including TRF2, TIN2, TPP1 and TRF1, all with similar 
effects seen on telomere binding after Hsp90 inhibition. These results suggest that the 
chaperones, Hsp90 in particular, play a role in facilitating telomere associated protein/telomere 
binding and/or telomere protein-protein interactions.  
 
TRF1 and Hsp90/Hsp70 
 As evidenced by the increase in TRF1’s telomere binding after Radicicol treatment and 
the interactions of TRF2, TIN2 and TPP1 with the chaperones, it was logical to examine TRF1’s 
interaction with Hsp90 and Hsp70 and how inhibition of Hsp90 affects TRF1. The interaction 
between Hsp90/TRF1 and Hsp70/TRF1 was effected by Radicicol treatment, although it differed 
from the results seen with TRF2. TRF2/chaperone interactions were greatly diminished at 8 
hours, while the TRF1/Hsp90 and TRF1/Hsp70 interactions were almost undetectable at 2 hours, 
returning consistently at the highest levels at 8 hours. As opposed to TRF2 where we saw no 
induction of ubiquitination, TRF1 appears to be substantially ubiquitinated after just 2 hours of 
RAD treatment. There was, however, no exportation to the cytoplasm, suggesting against a 
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cytosolic proteasome-mediated degradation pathway and for a nuclear degradation mechanism 
(von Mikecz, 2006). The disruption of TRF1/TRF2 colocalization with RAD treatment further 
suggests that inhibition of Hsp90 disrupts TRF1 function in the nucleus.  
The significant increase in chaperone/TRF1 interaction at 8 hours, which was so reduced 
at 8 hours for TRF2, may be the result of the chaperones “hopping” from one telomeric protein 
to the other due to an increased need for stabilization after treatment. Although both TRF1 and 
TRF2 act as protective factors at the telomere, they do so in different ways and, if repressed, 
present with differing consequences. Both TRF1 and TRF2 act as negative regulators of telomere 
length, repressing telomerase activity in cells. When TRF1 is repressed, telomere length 
increases as telomerase is able to extend telomeric repeats. When TRF2 is repressed, the G-
strand overhang shortens and there is an upregulation of DNA damage factors associating with 
the telomere (reviewed in: De Boeck, et al., 2009). The increase in telomere binding, along with 
the interactions seen between Hsp90 and TRF2 at 2-4 hours, suggests an early need for TRF2 to 
bind and protect the telomere (possibly as a means to protect the t-loop), as well as for 
responding to DNA damage events. The later upregulation of the Hsp90/TRF1 interaction may 
be the result of an increased need to prevent telomerase from binding to the telomere or to 
stabilize the telomere structure in order to prevent telomere degradation by nucleases.  
The observed difference between the TRF1/Hsp90 and TRF2/Hsp90 interactions could be 
affected by the differing half-life times of TRF1 and TRF2. It has been suggested that 
mammalian telomeres employ a protein counting mechanism as increased accumulation of TRF1 
and TRF2 at the telomere results in telomere shortening (Smorgorzewska, et al., 2000; van 
Steensel, et al., 1997). This is based on observations in yeast that there are a set number of 
TRF1/TRF2 binding sites and insertion of artificial binding sites results in telomere shortening 
97 
 
(Marcand, et al., 1997; Ancelin, et al., 2002). Photobleaching experiments showed that telomere 
length is maintained by dynamic binding of TRF1 and TRF2 with binding times of only 8 
seconds, so that the telomere is able to adapt quickly to telomerase or nuclease actions (Mattern, 
et al., 2004). TRF2 also has a “slow fraction” (27%) that binds for 11 minutes, which has been 
proposed to facilitate t-loop formation and stabilization. In fact, it has been shown that this 
slower fraction binds more stably to the telomere. When coupled with the “fast fraction”, it is 
suggested that TRF2 associates with telomeres in two complexes: one with a role in telomere 
length regulation and one regulating chromosome end protection (Mattern, et al., 2004). Hsp90 
interactions may be mediating the dynamic telomere binding of TRF2. It is possible that the 
TRF2 slow fraction is interacting early with Hsp90 and at 8 hours is lost; whereas, all TRF1 is 
continuously and quickly turning over, and the TRF1/Hsp90 interaction is effected much earlier. 
The longer the Hsp90 inhibition, the more disrupted the ability of the telomere binding protein 
(TRF1 or TRF2) to bind to the telomere, resulting in the decrease in telomere binding with 
chronic treatment.  
There may be a cell cycle-dependence for these interactions; however, because all 
Shelterin proteins are bound to or associated with the telomere throughout much of the cell cycle, 
this seems unlikely. There is also the possibility that the increased chaperone/TRF1 and TRF2 
interactions are effects of telomere protein-protein interactions. For example, TRF2 may bind 
stably to Rap1 in an immediate response to drug treatment, but TRF1/POT1’s interactions may 
need to be stabilized over longer periods of time, with Hsp90 facilitating these associations. The 
TIN2/TPP1/Hsp90 association may be evidence of this, as TPP1 tethers POT1 to TRF1 and 
TIN2 tethers TPP1 to TRF1 and TRF2 (reviewed in: De Boeck, et al., 2009), all of which may be 
mediated by Hsp90. 
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TRF2 has been identified as having different roles in chromatin remodeling where 
overexpression of TRF2 resulted in a decrease in histones H3 and H4 and subsequent disruption 
of nucleosomal spacing specific to telomeric chromatin (Benetti, et al., 2008). TRF2 can 
generate positive supercoiling with an ability to condense DNA. TRF2 wraps the DNA around 
itself and induces the untwisting of nearby DNA, allowing for strand invasion by positive 
supercoiling, as what is proposed to occur when forming the t-loop (Amiard, et al., 2007). TRF1 
also alters nucleosome structure by recognizing binding sites on telomeric nucleosomes and 
binding those sites through its TRFH DNA binding domain, which effects DNase I digestion 
patterns and indicates alterations in nucleosome core structure (Galati, et al., 2006). Therefore, 
the “doublet” FISH signal observed in day 3 Radicicol treated cells may be the result of either 
(or both) TRF1/TRF2 effecting telomeric chromatin structure, again implying that the 
chaperone/telomere binding protein interaction is dependent on an association with telomeric 
sequence and effects the ability of binding proteins to associate and function stably at the 
telomere.  
 
Summary 
Several telomeric proteins regulate telomere length, and shortened telomeres have been 
shown to be a marker for cancer (Griffith, et al., 1999; Odagiri, et al., 1994). With a shorter 
telomere and fewer associated telomere binding proteins, telomeres may be an ideal target for 
cancer treatment. In this work, we present novel findings that the chaperone proteins Hsp90 and 
Hsp70 interact with the telomere proteins TRF2, TRF1, TIN2 and TPP1, suggesting that we may 
be able to target telomeres via chaperone inhibition.  
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Our initial hypothesis was that chaperone proteins interact with the telomere independent 
of telomerase; therefore, the goal of this study was to elucidate the role of chaperones in both 
telomere structure and function by defining the relationship between the chaperones and 
telomeric proteins. We first identified chaperones Hsp90, Hsp70 and p23 bound to telomeric 
DNA through ChIP. We hypothesized that the chaperones were interacting with telomeric 
proteins, which was verified through Co-IP/Westerns with TRF1, TRF2, TIN2, and TPP1. 
Through pharmacologic inhibition of Hsp90 using Radicicol, we sought to define the functions 
of these interactions initially postulating that Hsp90 bound to TRF1 and TRF2 as a means to 
target the proteins for degradation. With chronic hsp90 inhibition, we found a transient change 
over time in telomere binding capability for TRF1 and TRF2 as well as a transient change in the 
Hsp90/TRF1 and Hsp90/TRF2 interactions over time. However, when examined by 
immunocytochemistry and Western there was no change in telomere protein localization or 
levels. Interestingly, RAD treatment resulted in an increase in TRF2/TPP1 interaction, two 
proteins that do not normally directly interact. No evidence of drug-induced ubiquitination was 
observed for TRF2, yet TRF1 did appear to be ubiquitinated and potentially degraded in the 
nucleus rather than the cytoplasm. These results suggest an important role for Hsp90 in telomeric 
protein-protein interactions and overall telomere structure and function. 
Because telomere associated proteins are so critical in maintaining genetic stability, an 
interaction with a stress protein such as Hsp90 may be an indicator that there are recurrent 
problems at chromosome ends that require a stress response. Alternatively, Hsp90 at the 
telomere may be required for continuously stabilizing proteins at the telomere, and continued 
inhibition may result in an inability of TRF1/TRF2 to properly bind the telomere resulting in 
telomeric deprotection and eventual genomic instability and senescence/apoptosis. Additionally, 
100 
 
the use of Hsp90 inhibitors in cancer treatment suggests a need to fully understand the 
mechanisms of action of these drugs. A study of Hsp90’s telomeric functions in cancer cells 
provides a better understanding of the role of current Hsp90 inhibitors and their mechanisms of 
action on the chromosome structure. The novel interactions between chaperones and telomere 
associated proteins identified here opens the door for a new area of study in telomere biology, 
and further understanding the role of these interactions in telomere protection may lead to 
additional targets for cancer therapy.  
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of References
102 
 
References Cited 
 
 
Akalin, A., Elmore, L.W., Forsythe, H.L., Amaker, B.A., McCollum, E.D., Nelson, P.S., 
Ware, J.L.,  and Holt, S.E. 2001. A novel mechanism for chaperone-mediated telomerase 
regulation during prostate cancer progression. Cancer Res. 61: 4791-6.  
Amiard, S., Doudeau, M., Pinte, S., Poulet, A., Lenain, C., Faivre-Moskalenko, C., Angelov, 
D., Hug, N., Vindigni, A., Bouvet, P., Paoletti, J., Gilson, E., and Giraud-Panis, M.J. 2007. 
A topological mechanism for TRF2-enhanced strand invasion. Nat Struct Mol Biol. 14: 147-54.  
Ancelin, K., Brunori, M., Bauwens, S.,  Koering, C.E., Brun, C., Ricoul, M., Pommier, J.P., 
Sabatier, L., and Gilson, E. 2002. Targeting assay to study the cis functions of human telomeric 
proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere 
degradation by TRF2. Mol. Cell. Biol. 22: 3474-3487. 
Baker, A.M., Fu, Q., Hayward, W., Lindsay, S.M., and Fletcher, T.M. 2009. The 
Myb/SANT domain of the telomere-binding protein TRF2 alters chromatin structure. Nucleic 
Acids Res. Epub ahead of print
Bailey, S.M., Meyne, J., Chen, D.J., Kurimasa, A., Li, G.C., Lehnert, B.E., and Goodwin, 
E.H. 1999. DNA double-strand break repair proteins are required to cap the ends of mammalian 
chromosomes. Proc Natl Acad Sci U S A. 96: 14899-904.  
 
Banjeri, U., et al. 2005. Phase 1 pharmacokinetic and pharmacodynamic study of 17-
allylamino-17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 
23: 4152-4161 
Benetti, R., Schoeftner, S., Muñoz, P., Blasco, M.A. 2008. Role of TRF2 in the assembly of 
telomeric chromatin. Cell Cycle. 7: 3461-8. 
 
Beliakoff, J. and Whitesell, L. 2004. Hsp90: an emerging target for breast cancer  
therapy. Anti-Cancer Drugs. 15: 651-662. 
Bilaud, T., Brun, C.,  Ancelin, K., Koering, C.E., Laroche, T., and Gilson, E. 1997. 
Telomeric localization of TRF2, a novel human telobox protein. Nat Genet. 17:236-9. 
Bilaud, T., Koering, C.E., Binet-Brasselet, E., Ancelin, K,. Pollice, A., Gasser, S.M., and 
Gilson, E. 1996. The telobox, a Myb-related telomeric DNA binding motif found in proteins 
from yeast, plants and human. Nucleic Acids Res. 24: 1294-303. 
Blasco, M.A. 2007. The epigenetic regulation of mammalian telomeres. Nat Rev Genet. 8: 299-
309. 
103 
 
Bogatcheva, N.V., Ma, Y., Urosev, D., and Gusev, N.B. 1999. Localization of calponin 
binding sites in the structure of 90 kDa heat shock protein (Hsp90). FEBS Lett. 1999 457: 369-
74. 
Bose, S., Weikl, T., Bügl, H., and Buchner, J. 1996. Chaperone function of Hsp90-associated 
proteins. Science. 274: 1715-7.  
Bradshaw, P.S., Stavropoulos, D.J., and Meyn, M.S. 2005. Human telomeric protein TRF2 
associates with genomic double-strand breaks as an early response to DNA damage. Nat Genet. 
37: 193-7.  
Broccoli, D., Smogorzewska, A., Chong, L., and de Lange, T. 1997. Human telomeres contain 
two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet. 17: 231-5. 
Bukau, B., Deuerling, E., Pfund, C., and Craig, E.A. 2000. Getting newly synthesized 
proteins into shape. Cell. 101: 119-22. 
Cech , T.R. 2004. Beginning to understand the end of the chromosome. Cell. 116: 273-9. 
Chang, W., Dynek, J.N., and Smith, S. 2003. TRF1 is degraded by ubiquitin-mediated 
proteolysis after release from telomeres. Genes Dev. 17: 1328-33.
Chen, Y.C., Teng, S.C., and Wu, K.J. 2009. Phosphorylation of telomeric repeat binding factor 
1 (TRF1) by Akt causes telomere shortening. Cancer Invest. 27: 24-8. 
Chong, L., van Steensel, B., Broccoli, D., Erdjument-Bromage, H., Hanish, J., Tempst, P., 
and de Lange, T. 1995. A human telomeric protein. Science. 270: 1663-7. 
Colgin, L. and Reddel, R. 2004. Telomere biology: a new player in the end zone. Curr Biol. 14: 
R901-2.  
Compton, S.A., Elmore, L.W., Haydu, K., Jackson-Cook, C.K., Holt, S.E. 2006. Induction of 
nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in 
tumor cells. Mol. Cell Biol. 26: 1452-1462. 
Counter, C.M. 1996. The roles of telomeres and telomerase in cell life span. Mutat Res.    366: 
45-63. 
 d'Adda di Fagagna, F., Hande, M.P., Tong, W.M., Lansdorp, P.M., Wang, Z.Q., and 
Jackson, S.P. 1999. Functions of poly(ADP-ribose) polymerase in controlling telomere length 
and chromosomal stability. Nat Genet. 23: 76-80. 
d'Adda di Fagagna, F., Hande, M.P., Tong, W.M., Roth, D., Lansdorp, P.M., Wang, Z.Q., 
and Jackson, S.P. 2001. Effects of DNA nonhomologous end-joining factors on telomere length 
and chromosomal stability in mammalian cells. Curr Biol. 11: 1192-6. 
104 
 
d'Adda di Fagagna, F., Teo, S.H., and Jackson, S.P. 2004. Functional links between telomeres 
and proteins of the DNA-damage response. Genes Dev. 18: 1781-99.  
De Boeck, G., Forsyth, R.G., Praet, M., and Hogendoorn, P.C. 2009. Telomere-associated 
proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. 
 J Pathol. 217:327-44. 
DeBoer, C., Meulman, P.A., Wnuk, R.J., and Peterson, D.H. 1970. Geldanamycin, a new 
antibiotic. J Antibiot (Tokyo). 23: 442-7.  
de Lange T. 2005. Shelterin: the protein complex that shapes and safeguards human telomeres. 
Genes Dev. 19: 2100-10.  
de Lange, T. and Petrini, J.H. 2000. A new connection at human telomeres: association of the 
Mre11 complex with TRF2. Cold Spring Harb Symp Quant Biol. 65: 265-73. 
Delmotte, P. and Delmotte-Plaque, J. 1953. A new antifungal substance of fungal origin. 
Nature. 171: 344. 
Demuth, I., Bradshaw, P.S., Lindner, A., Anders, M., Heinrich, S., Kallenbach, J., Schmelz, 
K., Digweed, M., Meyn, M.S., and Concannon, P. 2008. Endogenous hSNM1B/Apollo 
interacts with TRF2 and stimulates AT in response to ionizing radiation. DNA Repair 7: 1192-
201. 
 
Elmore, L.W., Rehder, C.W., Di, X., et al. 2002. Adriamycin-induced senescence in breast 
tumor cells involves functional p53 and telomere dysfunction. J. Biol Chem. 277: 35509-15. 
 
Elmore, L.W., Turner, K.C., Gollahan, L.S., London, M.R., Jackson-Cook, C.K., and Holt, 
S.E. 2002. Telomerase protects cancer-prone human cells from chromosomal instability and 
spontaneous immortalization. Cancer Biology and Therapy. 1: 391-397. 
Espejel, S., Franco, S., Rodríguez-Perales, S., Bouffler, S.D., Cigudosa, J.C., and Blasco, 
M.A. 2002. Mammalian Ku86 mediates chromosomal fusions and apoptosis caused by critically 
short telomeres. EMBO J. 21: 2207-19. 
Espejel, S., Franco, S., Sgura, A., Gae, D. Bailey, S.M., Taccioli, G.E., and Blasco, M.A. 
2002. Functional interaction between DNA-PKcs and telomerase in telomere length 
maintenance. EMBO J. 21: 6275-87. 
Fairall, L., Chapman, L., Moss, H., de Lange, T., and Rhodes, D. 2001. Structure of the 
TRFH dimerization domain of the human telomeric proteins TRF1 and TRF2. Mol Cell. 8: 351-
61.  
Fajkus, J., Kovarík, A., Královics, R., and Bezdĕk, M. 1995. Organization of telomeric and 
subtelomeric chromatin in the higher plant Nicotiana tabacum. Mol Gen Genet. 247: 633-8. 
105 
 
Forafonov, F., Toogun, O.A., Grad, I., Suslova, E., Freeman, B.C., and Picard, D. 2008. 
p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity. 
Mol Cell Biol. 28: 3446-56. 
 
Forsythe, H.L. Jarvis, J.L., Turner, J.W., Elmore, L.W., and Holt, S.E. 2001. Stable 
association of Hsp90 and p23 with human telomerase. J Biol. Chem. 276: 15571-15574. 
Freeman, B.C., Toft, D.O., and Morimoto, R.I. 1996. Molecular chaperone machines: 
chaperone activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein 
p23. Science. 274: 1718-20.  
 
Galati, A., Rossetti, L., Pisano, S., Chapman, L., Rhodes, D., Savino, M., and Cacchione, S. 
2006. The Human Telomeric Protein TRF1 Specifically Recognizes Nucleosomal Binding Sites 
and Alters Nucleosome Structure. J. Mol. Biol. 360: 377-385. 
Geng, X., Yang, Z-Q., and Danishefsky, S.J. 2004. Synthetic Development of Radiciol and 
Cycloproparadicicol: Highly Promising Anticancer Agents Targeting Hsp90. Synlett 8: 1325-
1333. 
Gilley, D., Tanaka, H., Hande, M.P., Kurimasa, A., Li, G.C., Oshimura, M., and Chen, D.J. 
2001. DNA-PKcs is critical for telomere capping. Proc Natl Acad Sci U S A. 98: 15084-8. 
Goetz, M.P., et al. 2005. Phase 1 trial of 17-allylamino-17-demethoxygeldanamycin in patients 
with advanced cancer. J. Clin. Oncol. 23: 1078-1087. 
Goytisolo, F.A., Samper, E., Edmonson, S., Taccioli, G.E., and Blasco, M.A. 2001. The 
absence of the dna-dependent protein kinase catalytic subunit in mice results in anaphase bridges 
and in increased telomeric fusions with normal telomere length and G-strand overhang. Mol Cell 
Biol. 21: 3642-51. 
Grem, J.L., et al. 2005. Phase 1 and pharmacologic study of 17-(allylamino)-17- 
demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 23: 1885- 
1893. 
Grenert JP, Johnson BD, Toft DO. 1999. The importance of ATP binding and hydrolysis by 
hsp90 in formation and function of protein heterocomplexes. J Biol Chem. 274: 17525-33. 
 
Griffith, J.K., Bryant, J.E., Fordyce, C.A., Gilliland, F.D., Joste N.E., and Moyzis, R.K.  
1999. Reduced telomeric DNA content is correlated with genomic instability and metastasis in 
invasive human breast carcinoma. Breast Cancer Res. Treat. 54: 59-64.  
 
Griffith, J.D., Comeau, L., Rosenfield, S., Stansel, R.M., Bianchi, A., Moss, H., and de 
Lange, T.  1999.  Mammalian telomeres end in a large duplex loop. Cell. 97: 503–514. 
Haber, J.E. 1998. The many interfaces of Mre11. Cell. 95: 583-6. 
106 
 
Hahn, J.S. 2009. The Hsp90 chaperone machinery: from structure to drug development. BMB 
Rep. 42: 623-30. 
Han, J., Qureshi, A.A., Prescott, J., Guo, Q., Ye, L., Hunter, D.J., and De Vivo, I. 2009. A 
prospective study of telomere length and the risk of skin cancer. J Invest Dermatol. 129: 415-21. 
Hanahan, D. and Weinberg, R. A. 2000. The Hallmarks of Cancer. Cell. 100: 57–70. 
Hartl, F. 1996. Molecular chaperones in cellular protein folding. Nature. 381: 571-9. 
Hartl, F.U. and Hayer-Hartl, M. 2002. Molecular chaperones in the cytosol: from nascent 
chain to folded protein. Science. 295: 1852-8. 
Her, Y.R., and Chung, I.K. 2009. Ubiquitin Ligase RLIM Modulates Telomere Length 
Homeostasis through a Proteolysis of TRF1. J Biol Chem. 284: 8557-66. 
Hershko, A., and Ciechanover, A. 1998. The ubiquitin system. Annu Rev Biochem. 67: 425-
79.  
Holt, S.E., Aisner, D.L., Baur, J., Tesmer, V.M., Dy, M., Ouellette, M., Toft, D.O., Trager, 
J.B., Morin, G.B., Wright, W.E., Shay, J.W., and White, M.A. 1999. Functional requirement 
of p23 and Hsp90 in telomerase complexes. Genes and Development 13: 817-826. 
Hsu, H.L., Gilley, D., Galande, S.A., Hande, M.P., Allen, B., Kim, S.H., Li, G.C., Campisi, 
J., Kohwi-Shigematsu, T., and Chen, D.J.  2000. Ku acts in a unique way at the mammalian 
telomere to prevent end joining. Genes Dev. 14:2807-12.  
Hunt, C.R., Dix, D.J., Sharma, G.G., Pandita, R.K., Gupta, A., Funk, M., and Pandita, T.K. 
2004. Genomic instability and enhanced radiosensitivity in Hsp70.1- and Hsp70.3-deficient 
mice. Mol Cell Biol. 24: 899-911. 
Jameel, A. et al. 1992. Clinical and biological significance of Hsp90α in human breast  
cancer. Int. J. Cancer. 50: 409-415. 
Jaco, I., Muñoz, P., and Blasco, M.A. 2004. Role of human Ku86 in telomere length 
maintenance and telomere capping. Cancer Res. 64: 7271-8. 
Jaco, I., Muñoz, P., Goytisolo, F., Wesoly, J., Bailey, S., Taccioli, G., and Blasco, M.A. 2003. 
Role of mammalian Rad54 in telomere length maintenance. Mol Cell Biol. 23: 5572-80. 
Jez, J.M., Chen, J.C., Rastelli, G., Stroud, R.M., and Santi, D.V. 2003. Crystal structure and 
molecular modeling of 17-DMAG in complex with human Hsp90. Chem Biol. 10: 361-8.  
Johnson, J.L., Beito, T.G., Krco, C.J., and Toft, D.O. 1994. Characterization of a novel 23-
kilodalton protein of unactive progesterone receptor complexes. Mol Cell Biol. 14: 1956-63. 
107 
 
Johnson J, Corbisier R, Stensgard B, and Toft D. 1996. The involvement of p23, hsp90, and 
immunophilins in the assembly of progesterone receptor complexes. J Steroid Biochem Mol 
Biol. 56(1-6 Spec No): 31-7. 
Johnson, J.L. and Toft, D.O. 1995. Binding of p23 and hsp90 during assembly with the 
progesterone receptor. Mol Endocrinol. 9: 670-8. 
Jolly, C. and Morimoto, R.I. 2000. Role of the heat shock response and molecular chaperones 
in oncogenesis and cell death. J Natl Cancer Inst. 92: 1564-72.  
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M.F., Fritz L., and Burrows  
J. 2003. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. 
Nature. 425: 407-410. 
 
Karleseder, J. 2003. Telomere repeat binding factors: keeping the ends in check. Cancer Letters. 
194: 189-197.  
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., and de Lange, T. 1999. p53- and ATM-
dependent apoptosis induced by telomeres lacking TRF2. Science. 283: 1321-5. 
Karlseder, J., Hoke, K., Mirzoeva, O.K., Bakkenist, C., Kastan, M.B., Petrini, J.H., and de 
Lange, T. 2004. The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-
dependent DNA damage response. PLoS Biol. 2: E240. 
Karlseder, J., Smogorzewska, A., and de Lange, T. 2002. Senescence induced by altered 
telomere state, not telomere loss. Science. 295: 2446-9. 
Kelleher, C., Kurth, I., and Lingner, J. 2005. Human protection of telomeres 1 (POT1) is a 
negative regulator of telomerase activity in vitro. Mol Cell Biol. 25: 808-18. 
Keppler BR, Grady AT, and Jarstfer MB. 2006. The biochemical role of the heat shock 
protein 90 chaperone complex in establishing human telomerase activity. J Biol Chem. 281: 
19840-8. 
Kim, H., Lee, O.H., Xin, H., Chen, L.Y., Qin, J., Chae, H.K., Lin, S.Y., Safari, A., Liu, D., 
and Songyang, Z.  2009. TRF2 functions as a protein hub and regulates telomere maintenance 
by recognizing specific peptide motifs. Nat Struct Mol Biol. 16: 372-9. 
Kim, M.K., Kang, M.R., Nam, H.W., Bae, Y.S., Kim, Y.S., and Chung, I.K. 2008. 
Regulation of telomeric repeat binding factor 1 binding to telomeres by casein kinase 2-mediated 
phosphorylation. J Biol Chem. 283: 14144-52. 
Kim, S.H., Beausejour, C., Davalos, A.R., Kaminker, P., Heo, S.J., and Campisi, J. 2004. 
TIN2 mediates functions of TRF2 at human telomeres. J Biol Chem. 279: 43799-804. 
108 
 
Kim, S.H., Kaminker, P., and Campisi, J. 1999. TIN2, a new regulator of telomere length in 
human cells. Nat Genet. 23: 405-12. 
Kishi, S., Zhou, X.Z., Ziv, Y., Khoo, C., Hill, D.E., Shiloh, Y., and Lu, K.P. 2001. Telomeric 
protein Pin2/TRF1 as an important ATM target in response to double strand DNA breaks. J Biol 
Chem. 276: 29282-91. 
Lanks, K.W. 1989. Temperature-dependent oligomerization of hsp85 in vitro. J Cell Physiol. 
140: 601-7. 
Lee, T.H., Perrem, K., Harper, J.W., Lu, K.P., and Zhou, X.Z. 2006. The F-box protein 
FBX4 targets PIN2/TRF1 for ubiquitin-mediated degradation and regulates telomere 
maintenance. J Biol Chem. 281: 759-68. 
Lees-Miller, S.P. and Anderson, C.W. 1989. The human double-stranded DNA-activated 
protein kinase phosphorylates the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal 
threonine residues. J Biol Chem. 264: 17275-80. 
Lindquist, S. and Craig, E.A. 1988. The heat-shock proteins. Annu Rev Genet. 22: 631-77.  
Liu, X., Bao, G., Huo, T., Wang, Z., He, X., and Dong, G. 2009. Constitutive telomere length 
and gastric cancer risk: Case-control analysis in Chinese Han population. Cancer Sci. 100: 1300-
1305. 
Liu, D., Safari, A., O'Connor, M.S., Chan, D.W., Laegeler, A., Qin, J., and Songyang, Z. 
2004. PTOP interacts with POT1 and regulates its localization to telomeres. Nat Cell Biol. 6: 
673-80. 
Loayza, D. and de Lange, T. 2003. POT1 as a terminal transducer of TRF1 telomere length 
control. Nature. 423: 1013-8. 
Marcand, S., Gilson, E., and Shore, D. 1997. A protein-counting mechanism for telomere 
length regulation in yeast. Science. 275: 986-990. 
Mattern, K.A., Swiggers, S.J., Nigg, A.L., Löwenberg, B., Houtsmuller, A.B., and Zijlmans, 
J.M. 2004. Dynamics of protein binding to telomeres in living cells: implications for telomere 
structure and function. Mol Cell Biol. 24: 5587-94.  
Matsutani, N., Yokozaki, H., Tahara, E., Tahara, H., Kuniyasu, H., Haruma, K., Chayama, 
K., Yasui, W., and Tahara, E. 2001. Expression of telomeric repeat binding factor 1 and 2 and 
TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol. 19: 507-12. 
Matsutani, N., Yokozaki, H., Tahara, E., Tahara, H., Kuniyasu, H., Kitadai, Y., Haruma, 
K., Chayama, K., Tahara, E., and Yasui, W. 2001. Expression of MRE11 complex (MRE11, 
RAD50, NBS1) and hRap1 and its relation with telomere regulation, telomerase activity in 
human gastric carcinomas. Pathobiology. 69: 219-24. 
109 
 
McLaughlin, S.H., Smith, H.W., and Jackson, S.E. 2002. Stimulation of the weak ATPase 
activity of human hsp90 by a client protein. J Mol Biol. 315: 787-98.  
 
McClintock, B. 1941. The stability of broken ends of chromosomes in Zea mays. Genetics. 26: 
234-282. 
 
Meeker, A.K., Hicks, J.L., Platz, E.A., et al. 2002. Telomere shortening is an early 
somatic DNA alteration in human prostate tumorigenesis. Cancer Research. 
62: 6405–9. 
 
Messaoudi, S., Peyrat, J.F., Brion, J.D., and Alami, M. 2008. Recent advances in Hsp90 
inhibitors as antitumor agents. Anticancer Agents Med Chem. 8: 761-82. 
  
Minami, Y., Kimura, Y., Kawasaki, H., Suzuki, K., and Yahara, I. 1994. The carboxy-
terminal region of mammalian HSP90 is required for its dimerization and function in vivo. Mol 
Cell Biol. 14: 1459-64.  
 
Mitchell, T.R.H., Glenfield, K., Jeyanthan, K., Zhu, X.D. 2009. Arginine methylation 
regulates telomere length and stability. Mol and Cell Biol. 29: 4918-4934. 
 
Muller, H.J. 1938. The remaking of chromosomes. Collecting Net. 8: 182–198. 
Muñoz, P., Blanco, R., Flores, J.M., and Blasco, M.A. 2005. XPF nuclease-dependent 
telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature 
aging and cancer.Nat Genet. 37:1063-71.  
Nathan, D.F. and Lindquist, S. 1995. Mutational analysis of Hsp90 function: interactions with 
a steroid receptor and a protein kinase. Mol Cell Biol. 15: 3917-25 
Nijjar, T., Bassett, E., Garbe, J., Takenaka, Y., Stampfer, MR, Gilley, D., and Yaswen, P. 
2005. Accumulation and altered localization of telomere-associated protein TRF2 in immortally 
transformed and tumor-derived human breast cells. Oncogene. 24: 3369-76. 
Odagiri, E., Kanada, N., Jibiki, K., Demura, R., Aikawa, E., and Demura, H. 1994. 
Reduction of telomeric length and c-erbB-2 gene amplification inhuman breast cancer, 
fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. 
Cancer. 73: 2978-2984. 
Oh, B.K., Kim, Y.J., Park, C., and Park, Y.N. 2005. Up-regulation of telomere-binding 
proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep 
hepatocarcinogenesis. Am J Pathol. 166: 73-80. 
Philippe, C., Coullin, P., and Bernheim, A. 1999. Double telomeric signals on single 
chromatids revealed by FISH and PRINS. Ann Genet. 42: 202-209. 
110 
 
Potts, P.R., and Yu, H. 2007. The SMC5/6 complex maintains telomere length in ALT cancer 
cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol. 14: 581-90. 
Pratt, W.B. and Toft, D.O. 1997. Steroid receptor interactions with heat shock protein and 
immunophilin chaperones. Endocr Rev. 18: 306-60. 
Pratt, W.B. and Toft, D.O. 2003. Regulation of signaling protein function and trafficking by 
the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 228: 111-33. 
Prodromou, C., Roe, S.M., O'Brien, R., Ladbury, J.E., Piper, P.W., and Pearl, L.H. 1997. 
Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 
molecular chaperone. Cell. 90: 65-75. 
Prodromou, C., Panaretou, B., Chohan, S., Siligardi, G., O’Brien, R., Ladbury, J.E., Roe, 
S.M., Piper, P.W., and Pearl, L.H. 2000. The ATPase cycle of Hsp90 drives a molecular 
“clamp” via transient dimerization of the N-terminal domains. EMBO J. 19: 4383-92. 
Rappold,  I., Iwabuchi, K., Date, T., and Chen, J. 2001. Tumor suppressor p53 binding 
protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol. 153: 613-20. 
Reddel, R.R. 2007. A SUMO ligase for ALT. Nat Struct Mol Biol. 14: 570-1.  
Ricaniadis, N., Kataki, A., Agnantis, N., Androulakis, G., Karajousis, C.P. 2001. Long term 
prognosis significance of Hsp70, c-myc and HLA-DR expression in patients with malignant 
melanoma. Eur J Surg Oncol. 27: 88-93. 
Richter, T., Sraetzki, G., Nelson, G., Melcher, M., Olijslagers, S., and von Zgliniski, T. 
2007. TRF2 overexpression diminishes repair of telomeric single-strand breaks and accelerates 
telomere shortening in human fibroblasts. Mech of Ageing and Dev. 128: 340-345. 
Richter, K., Walter, S., and Buchner, J.  2004. The Co-chaperone Sba1 connects the ATPase 
reaction of Hsp90 to the progression of the chaperone cycle. J Mol Biol. 342: 1403-13.  
Rog, O., Miller, K.M., Ferreira, M.G., and Cooper, J.P. 2009. Sumoylation of RecQ helicase 
controls the fate of dysfunctional telomeres. Mol Cell. 33: 559-69. 
Rooney, D., and Czepulkowski, B. 1992. Human Cytoogenetics: A Practical Approach, Vol II 
Malignancy and Aquired Abnormalities. (2nd Edition), Oxford Univrsity Press, New York. 198-
200. 
Ryan, M.T. and Pfanner, N. 2001. Hsp70 proteins in protein translocation. 
Adv Protein Chem. 59: 223-42. 
Sambrook, J., Fritsch, E.F., and Maniatis, T.. 1989. Molecular Cloning: A Laboratory 
Manual. (2nd Edition), Cold Spring Harbor Laboratory Press, New York. 1.25-1.28. 
111 
 
Samper, E., Goytisolo, F.A., Slijepcevic, P., van Buul, P.P., and Blasco, M.A. 2000. 
Mammalian Ku86 protein prevents telomeric fusions independently of the length of TTAGGG 
repeats and the G-strand overhang. EMBO Rep. 1: 244-52. 
Sausville, E.A., Tomaszewski, J.E., and Ivy, P.  2003. Clinical Development of 17- 
allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets. 3: 377-383. 
Schnur, R.C., Corman, M.L., Gallaschun, R.J., Cooper, B.A., Dee, M.F., Doty, J.L., Muzzi, 
M.L., Moyer, J.D., DiOrio, C.I., Barbacci, E.G., et al. 1995. Inhibition of the oncogene 
product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. 
J Med Chem. 38: 3806-12. 
Schulte, T.W., Akinaga, S., Soga, S., Sullivan, W., Stensgard, B., Toft, D., and Neckers, 
L.M. 1998. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important 
biologic activities with geldanamycin. Cell Stress Chaperones. 3: 100-8. 
Schulte, T.W., An, W.G., and Neckers, L.M. 1997. Geldanamycin-induced destabilization of 
Raf-1 involves the proteasome. Biochem Biophys Res Commun. 239: 655-9. 
Schultz, L.B., Chehab, N.H., Malikzay, A., and Halazonetis, T.D. 2000. p53 binding protein 1 
(53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol. 
151: 1381-90.  
 
Shammas, M.A., Koley, H., Beer, D.G., Li, C., Goyal, R.K., and Munshi, N.C. 2004. 
Growth arrest, apoptosis, and telomere shortening of Barrett’s-associated 
adenocarcinoma cells by a telomerase inhibitor. Gastroenterology. 126: 1337–46. 
 
Shay, J.W. and Bacchetti, S. 1997. A survey of telomerase activity in human cancer. Eur. J. 
Cancer. 33: 787-791. 
Smith, S. and de Lange, T. 1999. Cell cycle dependent localization of the telomeric PARP, 
tankyrase, to nuclear pore complexes and centrosomes. J Cell Sci. 112: 3649-56. 
Smith, S. and de Lange, T. 2000. Tankyrase promotes telomere elongation in human cells. Curr 
Biol. 10: 1299-302. 
Smith, S., Giriat, I., Schmitt, A., and de Lange, T. 1998. Tankyrase, a poly(ADP-ribose) 
polymerase at human telomeres. Science. 282: 1484-7. 
Stansel, R.M., de Lange, T., and Griffith, J.D. 2001. T-loop assembly in vitro involves  
binding of TRF2 near the 3’ telomeric overhang. EMBO Journal. 20: 5532-5540. 
  
Smogorzewska, A., Karlseder, J., Holtgreve-Grez, H., Jauch, A., and de Lange, T. 2002. 
DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol. 
12: 1635-44. 
112 
 
Smogorzewska, A., van Steensel, B,. Bianchi, A., Oelmann, S., Schaefer, M.R., Schnapp, G., 
de Lange, T. 2000. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol.   20: 
1659-68. 
Spengler, D. 2007. The protein kinase Aurora C phosphorylates TRF2. Cell Cycle. 6: 2579-80. 
Sreedhar, A.S., Kalmár, E., Csermely, P., and Shen, Y.F. 2004. Hsp90 isoforms: functions, 
expression and clinical importance. FEBS Lett. 562: 11-5.  
Supko, J.G., Hickman, R.L., Grever, M.R., and Malspeis, L. 1995. Preclinical pharmacologic 
evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 36: 305-15. 
Sullivan, W.P., Owen, B.A., and Toft, D.O. 2002. The influence of ATP and p23 on the 
conformation of hsp90. J Biol Chem. 277: 45942-8.  
Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U., and Pavletich, N.P. 1997. 
Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an 
antitumor agent. Cell. 89: 239-50.  
Takai, H., Smogorzewska, A., and de Lange, T. 2003. DNA damage foci at dysfunctional 
telomeres. Curr Biol. 13: 1549-56. 
Tanaka, H., Mendonca, M.S., Bradshaw, P.S., Hoelz, D.J., Malkas, L.H., Meyn, M.S., 
Gilley, D.  2005. DNA damage-induced phosphorylation of the human telomere-associated 
protein TRF2. Proc Natl Acad Sci U S A. 102:15539-44.  
 
Tarsounas, M., Muñoz, P., Claas, A., Smiraldo, P.G., Pittman, D.L., Blasco, M.A., and 
West, S.C. 2004. Telomere maintenance requires the RAD51D recombination/repair protein. 
Cell. 117: 337-47.  
Tian, Z.Q., Liu, Y., Zhang, D., Wang, Z., Dong, S.D., Carreras, C.W., Zhou, Y., Rastelli, 
G., Santi, D.V., and Myles, D.C. 2004. Synthesis and biological activities of novel 17-
aminogeldanamycin derivatives. Bioorg Med Chem. 12: 5317-29. 
Tommerup, H., Dousmanis, A., and de Lange, T. Unusual chromatin in human telomeres. Mol 
Cell Biol. 14: 5777-85. 
Toogun, O.A., Zeiger, W., and Freeman, B.C. 2007. The p23 molecular chaperone promotes 
functional telomerase complexes through DNA dissociation. Proc Natl Acad Sci U S A. 104: 
5765-70. 
van Overbeek, M. and de Lange, T. 2006. Apollo, an artemis-related nuclease, interacts with 
TRF2 and protects human telomeres in S phase. Curr. Biol. 16: 1295-1302. 
van Steensel, B. and de Lange, T. 1997. Control of telomere length by the human telomeric 
protein TRF1. Nature. 385: 740-3. 
113 
 
van Steensel, B., Smorgorzewska, A., and de Lange, T. 1998. TRF2 protects human telomeres 
from end-end fusions. Cell. 92: 401-413. 
 
Verger, A., Perdomo, J., and Crossley, M. 2003. Modification with SUMO. A role in 
transcriptional regulation. EMBO Rep. 4: 137-42. 
 
von Mikecz, A. 2006. The nuclear ubiquitin-proteasome system. J Cell Sci. 119: 1977-84. 
Wang, B., Matsuoka, S., Carpenter, P.B., and Elledge, S.J. 2002. 53BP1, a mediator of the 
DNA damage checkpoint. Science. 298: 1435-8. 
 
Wegele, H., Muller, L., Buchner, J. 2004. Hsp70 and Hsp90 – a relay team for protein folding. 
Rev. Physiol. Biochem, Pharmacol. 151: 1-44. 
 
Whitesell, L., Mimnaugh, E.G., de Costa, B., Myers, C.E., and Neckers, L.M. 1994.  
Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by  
benzoquinone ansamycins: essential role for stress proteins in oncogeneic  
transformation. Proc Natl Acad Sci USA. 91: 8324-8328. 
Wilson VG, and Rangasamy D. 2001. Intracellular targeting of proteins by sumoylation. Cell 
Res. 271: 57-65.  
Wu, G., Lee, W.H., and Chen, P.L.  2000. NBS1 and TRF1 colocalize at promyelocytic 
leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication 
of NBS1 in alternative lengthening of telomeres. J.Biol Chem. 275: 30618-22.  
 
Wu, X., Amos, C.I., Zhu, Y., et al. 2003. Telomere dysfunction: a potential cancer 
predisposition factor. J Natl Cancer Inst. 95: 1211–18. 
Wu, Z.Q., Yang, X., Weber, G., and Liu, X. 2008. Plk1 phosphorylation of TRF1 is essential 
for its binding to telomeres. J Biol Chem. 283: 25503-13. 
Xhemalce, B., Riising, E.M., Baumann, P., Dejean, A., Arcangioli, B., and Seeler, J.S. 2007.  
Role of SUMO in the dynamics of telomere maintenance in fission yeast. Proc Natl Acad Sci U 
S A. 104: 893-8. 
Yano, M., Naito, Z., Tanaka, S., and Asano, G. 1996. Expression and the roles of heat shock 
proteins in human breast cancer. Jpn. J. Cancer. Res. 87: 908-915. 
Ye, J.Z., Donigian, J.R., van Overbeek, M., Loayza, D., Luo, Y., Krutchinsky, A.N., Chait, 
B.T., and de Lange, T. 2004. TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the 
TRF2 complex on telomeres. J Biol Chem. 279:47264-71. 
114 
 
Ye, J.Z., Hockemeyer, D., Krutchinsky, A.N., Loayza, D., Hooper, S.M., Chait, B.T., and de 
Lange, T. 2004. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 
to the TIN2/TRF1 complex. Genes Dev. 18: 1649-54. 
Young, J.C. and Hartl, F.U. 2000. Polypeptide release by Hsp90 involves ATP hydrolysis and 
is enhanced by the co-chaperone p23. EMBO J. 19: 5930-40. 
Yurchenko, V., Xue, Z., Gama, V., Matsuyama, S., and Sadofsky, M.J. 2008. Ku70 is 
stabilized by increased cellular SUMO. Biochem Biophys Res Commun. 366: 263-8. 
Zhao, X., and Blobel, G. 2005. A SUMO ligase is part of a nuclear multiprotein complex that 
affects DNA repair and chromosomal organization. Proc Natl Acad Sci U S A. 102: 4777-82. 
Zhong, Z., Shiue, L., Kaplan, S., and de Lange, T. 1992. A mammalian factor that binds 
telomeric TTAGGG repeats in vitro. Mol Cell Biol. 12: 4834-43. 
Zhu, X.D., Küster, B., Mann, M., Petrini, J.H., and de Lange, T.  2000. Cell-cycle-regulated 
association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet. 25: 347-52. 
115 
 
 
 
 
 
 
 
 
Appendix
116 
 
Appendix 
Post-Translational Modification of TRF2 through SUMOylation 
 
INTRODUCTION 
Post-translational modification of telomeric proteins has not been widely studied, 
although a number of protein kinases associate at the telomere to aid in telomere maintenance, 
including ATM and DNA-PKcs (d’Adda di Fagagna, et al., 2004). While many telomeric 
proteins have been shown to be phosphorylated or ubiquitinated, little has been reported with 
regard to TRF2 post-translational modifications. 
SUMOylation is a form of post-translational modification with a pathway similar to 
ubiquitin, although its roles differ significantly from ubiquitin. SUMOylation is involved in 
protein-protein interactions, DNA binding, protein localization, and trafficking, as well as 
facilitating degradation. Recent evidence suggests that SUMOylation may have a role in 
Alternative Lengthening of Telomeres (ALT) cells, which employs homologous recombination 
rather than telomerase to lengthen telomeres, with some evidence for TRF2/SUMO alteration 
(Potts and Yu, 2007; Zhao and Blobel, 2005; Xhemalce, et al., 2007). Interestingly, there is no 
published evidence of Shelterin protein SUMOylation in telomerase-positive cells. 
We hypothesized that TRF2 is SUMOylated in all cells. In an effort to determine if this 
occurs in telomerase-positive cells as well as determine the functional significance of this 
modification, various TRF2 fusion proteins and mutants were generated to examine the role 
SUMO plays in regulating TRF2. TRF2 is an important protein at the telomere whose main 
function is to protect the telomere ends, preventing telomere dysfunction and genomic instability. 
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Elucidation of the regulation of TRF2 will provide a better understanding of its role in telomere 
biology and protection.  
 
 
RESULTS 
SUMOylation of TRF2  
Because SUMOylated proteins are involved in DNA binding and TRF2 is a telomeric-
DNA binding protein, SUMOylation of TRF2 may have major implications in its ability to 
perform its functions. Potential SUMOylation sites in the TRF2 amino acid sequence were 
identified using the Abgent SUMOPLOT program (Figure 38). Possible SUMOylation 
consensus sequences (ψKxE) were predicted, and those with the highest probability were 
identified for further examination. The sites that are removed in the DNTRF2 sequence were also 
identified to ensure that no high probability SUMOylation sites chosen were contained in the 
eliminated N- or C- terminus because it was hypothesized that both TRF2 and DNTRF2 were 
SUMOylated, as the sites with the highest probability were located within the DNTRF2 sequence 
(Figure 39).  
The two predicted SUMOylation sites identified and scored with the highest probability 
of being TRF2 SUMOylation sites (Figure 38) were chosen for further examination of their 
potential role in TRF2’s post-translational regulation (Figure 41). Site-directed mutagenesis was 
performed to determine how un-SUMOylated TRF2 functions in the cell. The two positions 
chosen were at the lysine (K) at amino acid 140 (sequence: IKTE), located at 442-444 bp, and 
amino acid 245 (sequence: LKSE), located at 857-859 bp (Figures 38, 39 and 40). The lysine 
codon AAA was mutated to an arginine (R) codon AGA for both sites, as previously reported 
(Potts and Yu, 2007). The results of previous studies have also suggested that a double mutation  
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Chosen for 
site-directed
mutagenesis
No. Position Group Score
1 K140 NVLEM IKTE FTLTE 0.94
2 K245 MAKKA LKSE SAASS
3 K307 SEAAF AK
0.91
LD QKDLV 0.79
4 K459 EESEWVKAG VQKYG 0.76
5 K255 AASSTGKED KQPAP 0.67
6 K405 PGEKN PKVP KGKWN 0.50
7 K33 KNKRP RKDE NESSA 0.44
8 K267 APGPV EKPP REPAR 0.39
9 K258 STGKE DKQP APGPV 0.39
10 K402 QPLPG EKNP KVPKG 0.39
11 K464 VKAGV QKYG EGNWA 0.33
 
 
Figure 38. SUMOylation sites chosen to mutate for site-directed mutagenesis. Using the 
Abgent SUMOPLOT program, the possible TRF2 SUMOylation sites were given scores. The 
two highest scoring possible sequences were chosen for site-directed mutagenesis at position 
K140 and K245.  The lysine at K140 (IKTE) was mutated from the amino acid sequence AAA to 
and arginine, sequence AGA. The lysine at K245 (LKSE) was also mutated to an arginine (AAA 
to AGA). 
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201 EKNLAHPVIQ NFSYETFQQK MLRFLESHLD DAEPYLLTMA KKALKSESAA 
101 LRVMQCLSRI EEGENLDCSF DMEAELTPLE SAINVLEMIK TEFTLTEAVV 
TRF2 Sumoylation
1 MAGGGGSSDG SGRAAGRRAS RSSGRARRGR HEPGLGGPAE RGAGEARLEE 
51 AVNRWVLKFY FHEALRAFRG SRYGDFRQIR DIMQALLVRP LGKEHTVSRL 
94%
151 ESSRKLVKEA AVIICIKNKE FEKASKILKK HMSKDPTTQK LRNDLLNIIR 
91%
67%
251 SSTGKEDKQP APGPVEKPPR EPARQLRNPP TTIGMMTLKA AFKTLSGAQD 
79%
301 SEAAF KDLVLPTQAL PASPALKNKR PRKDENESSA PADGEGGSEL 
351 QPKNKRMTIS RLVLEEDSQS TEPSAGLNSS QEAASAPPSK PTVLNQPLPG 
401 EKNPKVPKGK WNSSNGVEEK ETWVEEDELF QVQAAPDEDS TTNITKKQKW 
76%
AKLDQ 
451 TVEESEWVKA GVQKYGEGNW AAISKNYPFV NRTAVMIKDR WRTMKRLGMN 
DN
DN
 
 
Figure 39. Predicted SUMOylation sites of TRF2. Using the Abgent SUMOPLOT program, 
predicted SUMOylation sites in the TRF2 amino acid sequence were found. Two with the 
highest probability are shown boxed while 3 others are highlighted. The sites where the 
DNTRF2 amino acid sequence stops and starts are indicated by arrows.   
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B
K140R
mutant
K245R
mutant
 
 
Figure 40. Sequence verification of TRF2 site-directed mutagenesis. A. Chromatogram of 
original sequence of K140 compared to the mutation. Highlighted base pair indicates mutation of 
A to G, changing the amino acid sequence from lysine to arginine. B. Chromatogram of original 
sequence of K245 compared to mutation. Highlighted base pair indicates mutation of A to G, 
changing the amino acid sequence from lysine to arginine. 
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Figure 41. In vitro SUMOylation of TRF2. TRF2, DN-TRF2, mutant K140 TRF2, mutant 
K245 TRF2 and double mutant K140/K245 TRF2 were synthesized using the 35S labeled RRL 
transcription translation (TnT) system. Samples were then assayed for SUMOylation using the 
Vaxron In Vitro SUMOylation Assay kit in the presence of SUMO-1 and SUMOylation enzymes 
Ubc9 and SAE1/SAE2. SUMOylated samples were run next to unSUMOylated samples with 
TRF2 serving as a positive control and DN-TRF2 serving as a negative control. 
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is required for complete loss of SUMOylation of telomeric proteins, as a single mutation of a 
SUMO binding site is not sufficient (Potts and Yu, 2007). Therefore, we also created a SUMO 
double mutant at amino acids 140 and 245 with both lysines mutated to arginines. The TRF2 
plasmid, pcDNA3-TRF2full, was used in the Stratagene QuikChange II Site-Directed 
Mutagenesis Kit and sequenced (Figure 40).  
To determine if TRF2 is SUMOylated, we first examined in vitro synthesized TRF2’s 
SUMOylation. Both TRF2 and DNTRF2 were synthesized using the RRL system and then 
assayed for SUMOylation with the Vaxron SUMOylation kit. Samples were synthesized in the 
presence of the SUMO protein SUMO1 as well as the SUMO activating enzymes SAE1/SAE2 
and the SUMO conjugating enzyme Ubc9. SUMO adds 11 kDa to the protein and the bands 
above the TRF2 band (at approximately 69 kDa) indicate TRF2 and not DNTRF2 is 
SUMOylated (Figure 41). Two repeated experiments confirm that TRF2 is SUMOylated (data 
not shown). A possible SUMOylation site with moderate probability (76%) was located outside 
of the DNTRF2 sequence, and DNTRF2 appears to not be SUMOylated (Figure 38, Figure 39, 
Figure 41), suggesting an important site to be explored further. To test the site-directed mutations 
in vitro, samples were synthesized using the RRL system and assayed with the Vaxron 
SUMOylation kit. Unexpectedly, only the double mutant resulted in a modest loss of TRF2’s 
SUMOylated bands (Figure 41). Further experiments involving transfection of the double mutant 
into telomerase positive cells to examine effects on TRF2’s localization, protein-protein 
interactions, and degradation are currently being conducted. 
To confirm that TRF2 is SUMOylated in telomerase positive cells, MCF7 cells were 
treated with N-Ethylmalemide (NEM), which prevents SUMO proteases from removing the 
SUMO moiety from the target protein after cell lysis. Whole cell extracts were  
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Figure 42. In cell SUMOylation of TRF2. Whole cell extracts were processed from MCF7 cells 
in the presence of the chemical NEM, which prevents SUMO proteases from cleaving the 
SUMO off proteins during the extraction process. Samples were then immunoprecipitated for 
TRF2 (A) or the Pan SUMO antibody (B) (which recognizes SUMO1 and SUMO2/3). Western 
blots were probed as indicated. TRF2 migrates at 65/69 kDa, the higher bands indicate SUMO 
modification of TRF2 (A and B). 
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immunoprecipitated for TRF2 or PAN-SUMO, which recognizes SUMO1 and SUMO2/3 
(Figure 42). The higher molecular weight bands observed indicate that TRF2 is SUMOylated in 
MCF7 cells (Figure 42).  
 
Summary 
 SUMOylation of TRF2 has been identified in ALT cells, along with the SUMOylation of 
TRF1, TIN2 and Rap1 (Potts and Yu, 2007). However, in telomerase positive or normal cells, 
this modification has yet to be recognized. Possible SUMOylation sites were predicted and 
SUMOylation of TRF2 was verified both in vitro and in telomerase positive MCF7 cells to 
determine the function of its SUMOylation. Mutation of two of the predicted sites, those with the 
highest probability of being true SUMO binding sites at K140 and K245, resulted in only a 
modest decrease in SUMOylation in vitro when combined.  
DNTRF2 appeared to not be SUMOylated. The two SUMO sites mutated in these 
experiments remained within the DNTRF2 coding sequence and because the DNTRF2 truncation 
was not SUMOylated, a third site located outside of the DNTRF2 sequence (at K459) could play 
a major role in DNTRF2’s effects in telomerase-positive cells. DNTRF2, when overexpressed in 
cells, results in end-end fusions and genomic instability, eventually leading to cellular 
senescence or death (van Steensel, et al., 1998; Karlseder, et al., 1999). The elimination of the 
SUMO moiety at the K459 binding site could be a factor in this damage response. Mutation of 
K459 will be performed to determine if this third site is an important SUMO binding site for 
proper function of TRF2. 
SUMOylation, unlike ubiquitination, has a variety of functions in the cell, including 
localization, degradation, and protein-protein interactions. It is possible that SUMOylation of 
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TRF2 functions in maintaining TRF2’s interactions with other telomere proteins, although an 
examination of TRF2/Rap1 or TRF2/TIN2 interactions using the SUMO-deficient mutant of 
TRF2 would need to be performed. PARP1, a TRF2 interacting protein that functions to 
poly(ADP)-ribosylate TRF2, and DNA-PKcs, a protein kinase that binds TRF2, may be affected 
by the inhibition of TRF2 SUMOylation, possibly repressing their role in post-translation 
modification (reviewed in: De Boeck, et al., 2009). Thus, SUMOylation may be having an effect 
on other post-translational modifications of TRF2.  
The importance of TRF2 in maintaining and protecting the telomere requires a complete 
understanding of its regulation and post-translation modifications. Little is known in the 
literature about modifications of TRF2 in telomerase-expressing tumor cells.  We have identified 
a novel post-translational modification of TRF2 by SUMOylation in telomerase-positive cancer 
cells. In an effort to determine the functional significance of this modification, the various TRF2 
SUMO-mutants we have created may lead to elucidation of a role for SUMO in maintaining 
telomere protein-protein interactions, localization, or degradation.   
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